4D MOLECULAR THERAPEUTICS, INC.35104E100US35104E100106/17/2026Election of three Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected. Nancy Miller-RichDIRECTOR ELECTIONSISSUER418620FOR41862FOR19 4D MOLECULAR THERAPEUTICS, INC.35104E100US35104E100106/17/2026Election of three Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected. John F. Milligan, Ph.D.DIRECTOR ELECTIONSISSUER418620FOR41862FOR19 4D MOLECULAR THERAPEUTICS, INC.35104E100US35104E100106/17/2026Election of three Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected. Shawn Cline Tomasello, MBADIRECTOR ELECTIONSISSUER418620FOR41862FOR19 4D MOLECULAR THERAPEUTICS, INC.35104E100US35104E100106/17/2026Ratification of the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER418620FOR41862FOR19 4D MOLECULAR THERAPEUTICS, INC.35104E100US35104E100106/17/2026Approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers (''say-on-pay vote'').SECTION 14A SAY-ON-PAY VOTESISSUER418620FOR41862FOR19 ABBOTT LABORATORIES002824100US002824100004/24/2026Election of 12 Directors: N. AhujaDIRECTOR ELECTIONSISSUER219890FOR21989FOR19 ABBOTT LABORATORIES002824100US002824100004/24/2026Election of 12 Directors: C. Babineaux-FontenotDIRECTOR ELECTIONSISSUER219890FOR21989FOR19 ABBOTT LABORATORIES002824100US002824100004/24/2026Election of 12 Directors: S. E. BlountDIRECTOR ELECTIONSISSUER219890FOR21989FOR19 ABBOTT LABORATORIES002824100US002824100004/24/2026Election of 12 Directors: R. B. FordDIRECTOR ELECTIONSISSUER219890FOR21989FOR19 ABBOTT LABORATORIES002824100US002824100004/24/2026Election of 12 Directors: P. GonzalezDIRECTOR ELECTIONSISSUER219890FOR21989FOR19 ABBOTT LABORATORIES002824100US002824100004/24/2026Election of 12 Directors: M. A. KumbierDIRECTOR ELECTIONSISSUER219890FOR21989FOR19 ABBOTT LABORATORIES002824100US002824100004/24/2026Election of 12 Directors: D. W. McDewDIRECTOR ELECTIONSISSUER219890FOR21989FOR19 ABBOTT LABORATORIES002824100US002824100004/24/2026Election of 12 Directors: N. McKinstryDIRECTOR ELECTIONSISSUER219890FOR21989FOR19 ABBOTT LABORATORIES002824100US002824100004/24/2026Election of 12 Directors: M. G. O'GradyDIRECTOR ELECTIONSISSUER219890FOR21989FOR19 ABBOTT LABORATORIES002824100US002824100004/24/2026Election of 12 Directors: M. F. RomanDIRECTOR ELECTIONSISSUER219890FOR21989FOR19 ABBOTT LABORATORIES002824100US002824100004/24/2026Election of 12 Directors: D. J. StarksDIRECTOR ELECTIONSISSUER219890FOR21989FOR19 ABBOTT LABORATORIES002824100US002824100004/24/2026Election of 12 Directors: J. G. StrattonDIRECTOR ELECTIONSISSUER219890FOR21989FOR19 ABBOTT LABORATORIES002824100US002824100004/24/2026Ratification of Ernst & Young LLP As AuditorsAUDIT-RELATEDISSUER219890FOR21989FOR19 ABBOTT LABORATORIES002824100US002824100004/24/2026Say on Pay - An Advisory Vote on the Approval of Executive CompensationSECTION 14A SAY-ON-PAY VOTESISSUER219890FOR21989FOR19 ABBOTT LABORATORIES002824100US002824100004/24/2026Approval of the Abbott Laboratories 2026 Incentive Stock ProgramCOMPENSATIONISSUER219890FOR21989FOR19 ABBOTT LABORATORIES002824100US002824100004/24/2026Approval of the Abbott Laboratories 2026 Employee Stock Purchase Plan for Non-U.S. EmployeesCOMPENSATIONISSUER219890FOR21989FOR19 ABBVIE INC.00287Y109US00287Y109105/08/2026Election of Class II Directors Jennifer L. DavisDIRECTOR ELECTIONSISSUER597840FOR59784FOR19 ABBVIE INC.00287Y109US00287Y109105/08/2026Election of Class II Directors Melody B. MeyerDIRECTOR ELECTIONSISSUER597840FOR59784FOR19 ABBVIE INC.00287Y109US00287Y109105/08/2026Election of Class II Directors Robert A. MichaelDIRECTOR ELECTIONSISSUER597840FOR59784FOR19 ABBVIE INC.00287Y109US00287Y109105/08/2026Election of Class II Directors Frederick H. WaddellDIRECTOR ELECTIONSISSUER597840FOR59784FOR19 ABBVIE INC.00287Y109US00287Y109105/08/2026Ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2026AUDIT-RELATEDISSUER597840FOR59784FOR19 ABBVIE INC.00287Y109US00287Y109105/08/2026Say on Pay - An advisory vote on the approval of executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER597840FOR59784FOR19 ABBVIE INC.00287Y109US00287Y109105/08/2026Approval of a management proposal regarding amendment of the certificate of incorporation to eliminate supermajority votingSHAREHOLDER RIGHTS AND DEFENSESISSUER597840FOR59784FOR19 ABBVIE INC.00287Y109US00287Y109105/08/2026Stockholder Proposal - to Adopt a Policy to Require an Independent ChairCORPORATE GOVERNANCESECURITY HOLDER597840AGAINST59784FOR19 ABIVAX SAF00182109FR001233328405/11/2026Approve Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER86950FOR8695FOR19 ABIVAX SAF00182109FR001233328405/11/2026Approve Consolidated Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER86950FOR8695FOR19 ABIVAX SAF00182109FR001233328405/11/2026Approve Treatment of LossesCAPITAL STRUCTUREISSUER86950FOR8695FOR19 ABIVAX SAF00182109FR001233328405/11/2026Approve Auditors' Special Report on Related-Party Transactions Mentioning the Absence of New TransactionsAUDIT-RELATEDISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Reelect Sylvie Grégoire as DirectorDIRECTOR ELECTIONSISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Reelect June Lee as DirectorDIRECTOR ELECTIONSISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Reelect Troy Ignelzi as DirectorDIRECTOR ELECTIONSISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Approve Compensation ReportCOMPENSATIONISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Approve Compensation of Marc de Garidel, CEOSECTION 14A SAY-ON-PAY VOTESISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Approve Compensation of Sylvie Grégoire, Chairwoman of the BoardSECTION 14A SAY-ON-PAY VOTESISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Approve Compensation Report of Corporate OfficersCOMPENSATIONISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Approve Remuneration Policy of Chairwoman of the BoardSECTION 14A SAY-ON-PAY VOTESISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Approve Remuneration Policy of CEOSECTION 14A SAY-ON-PAY VOTESISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Approve Remuneration Policy of DirectorsSECTION 14A SAY-ON-PAY VOTESISSUER86950FOR8695FOR19 ABIVAX SAF00182109FR001233328405/11/2026Authorize Repurchase of Up to 10 Percent of Issued Share CapitalCAPITAL STRUCTUREISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Authorize Decrease in Share Capital via Cancellation of Repurchased SharesCAPITAL STRUCTUREISSUER86950FOR8695FOR19 ABIVAX SAF00182109FR001233328405/11/2026Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 750,000CAPITAL STRUCTUREISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 750,000CAPITAL STRUCTUREISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 750,000CAPITAL STRUCTUREISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Approve Issuance of Equity or Equity-Linked Securities for Qualified Investors, up to Aggregate Nominal Amount of EUR 237,873.56CAPITAL STRUCTUREISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries in the Framework of an Equity Line on the American Market, up to Aggregate Nominal Amount of EUR 20,000CAPITAL STRUCTUREISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 237,873.56CAPITAL STRUCTUREISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote AboveCAPITAL STRUCTUREISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Authorize Capitalization of Reserves of Up to EUR 750,000 for Bonus Issue or Increase in Par ValueCAPITAL STRUCTUREISSUER86950FOR8695FOR19 ABIVAX SAF00182109FR001233328405/11/2026Authorize Capital Increase of up to 20 Percent of Issued Capital for Contributions in KindEXTRAORDINARY TRANSACTIONSISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Authorize Capital Increase of Up to EUR 750,000 for Future Exchange OffersCAPITAL STRUCTUREISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Set Total Limit for Capital Increase to Result from Issuance Requests Under Items 17-22 and 25-26 at EUR 750,000CAPITAL STRUCTUREISSUER86950FOR8695FOR19 ABIVAX SAF00182109FR001233328405/11/2026Authorize up to 10 Percent of Issued Capital for Use in Stock Option PlansCOMPENSATIONISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Approve Issuance of Warrants (Bons) Reserved for Services Providers, Consultants, Employees and Executives, up to 10 Percent of Issued Share CapitalCOMPENSATIONISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock PlansCOMPENSATIONISSUER86950AGAINST8695AGAINST19 ABIVAX SAF00182109FR001233328405/11/2026Set Total Limit for Capital Increase to Result from Issuance Requests Under Items 28-30, at 10 Percent of Issued CapitalCAPITAL STRUCTUREISSUER86950FOR8695FOR19 ABIVAX SAF00182109FR001233328405/11/2026Authorize Capital Issuances for Use in Employee Stock Purchase PlansCOMPENSATIONISSUER86950FOR8695FOR19 ABIVAX SAF00182109FR001233328405/11/2026Authorize Filing of Required Documents/Other FormalitiesCORPORATE GOVERNANCEISSUER86950FOR8695FOR19 AGILENT TECHNOLOGIES, INC.00846U101US00846U101603/18/2026Election of Directors: To elect four directors to a three-year term. At the annual meeting, the Board of Directors intends to present the following nominees for election as directors: Judy Gawlik BrownDIRECTOR ELECTIONSISSUER1240410FOR124041FOR19 AGILENT TECHNOLOGIES, INC.00846U101US00846U101603/18/2026Election of Directors: To elect four directors to a three-year term. At the annual meeting, the Board of Directors intends to present the following nominees for election as directors: Sue H. RatajDIRECTOR ELECTIONSISSUER1240410FOR124041FOR19 AGILENT TECHNOLOGIES, INC.00846U101US00846U101603/18/2026Election of Directors: To elect four directors to a three-year term. At the annual meeting, the Board of Directors intends to present the following nominees for election as directors: George A. Scangos, Ph.D.DIRECTOR ELECTIONSISSUER1240410FOR124041FOR19 AGILENT TECHNOLOGIES, INC.00846U101US00846U101603/18/2026Election of Directors: To elect four directors to a three-year term. At the annual meeting, the Board of Directors intends to present the following nominees for election as directors: Dow R. WilsonDIRECTOR ELECTIONSISSUER1240410FOR124041FOR19 AGILENT TECHNOLOGIES, INC.00846U101US00846U101603/18/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1240410FOR124041FOR19 AGILENT TECHNOLOGIES, INC.00846U101US00846U101603/18/2026To ratify the Audit and Finance Committee's appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm.AUDIT-RELATEDISSUER1240410FOR124041FOR19 AGILENT TECHNOLOGIES, INC.00846U101US00846U101603/18/2026To approve an amendment to Agilent's Third Amended and Restated Certificate of Incorporation to declassify the Board of Directors over a three-year period.SHAREHOLDER RIGHTS AND DEFENSESISSUER1240410FOR124041FOR19 AGIOS PHARMACEUTICALS, INC.00847X104US00847X104606/18/2026To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified. Rahul Ballal, Ph.D.DIRECTOR ELECTIONSISSUER995950FOR99595FOR19 AGIOS PHARMACEUTICALS, INC.00847X104US00847X104606/18/2026To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified. Brian GoffDIRECTOR ELECTIONSISSUER995950FOR99595FOR19 AGIOS PHARMACEUTICALS, INC.00847X104US00847X104606/18/2026To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified. Cynthia SmithDIRECTOR ELECTIONSISSUER995950WITHHOLD99595AGAINST19 AGIOS PHARMACEUTICALS, INC.00847X104US00847X104606/18/2026To vote, on an advisory basis, to approve the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER995950FOR99595FOR19 AGIOS PHARMACEUTICALS, INC.00847X104US00847X104606/18/2026To approve an amendment to the Agios Pharmaceuticals, Inc. 2023 Stock Incentive Plan, as Amended, to increase the number of shares of common stock available thereunder by 2,000,000 shares.COMPENSATIONISSUER995950FOR99595FOR19 AGIOS PHARMACEUTICALS, INC.00847X104US00847X104606/18/2026To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER995950FOR99595FOR19 AKESO, INC.G0146B103KYG0146B103206/29/2026Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER950000FOR95000FOR19 AKESO, INC.G0146B103KYG0146B103206/29/2026Elect Li Baiyong as DirectorDIRECTOR ELECTIONSISSUER950000FOR95000FOR19 AKESO, INC.G0146B103KYG0146B103206/29/2026Elect Wang Zhongmin Maxwell as DirectorDIRECTOR ELECTIONSISSUER950000FOR95000FOR19 AKESO, INC.G0146B103KYG0146B103206/29/2026Elect Xie Ronggang as DirectorDIRECTOR ELECTIONSISSUER950000FOR95000FOR19 AKESO, INC.G0146B103KYG0146B103206/29/2026Authorize Board to Fix Remuneration of DirectorsCOMPENSATIONISSUER950000FOR95000FOR19 AKESO, INC.G0146B103KYG0146B103206/29/2026Approve Ernst & Young as Auditors and Authorize Board to Fix Their RemunerationAUDIT-RELATEDISSUER950000FOR95000FOR19 AKESO, INC.G0146B103KYG0146B103206/29/2026Approve Issuance of Equity or Equity-Linked Securities without Preemptive RightsCAPITAL STRUCTUREISSUER950000AGAINST95000AGAINST19 AKESO, INC.G0146B103KYG0146B103206/29/2026Authorize Repurchase of Issued Share CapitalCAPITAL STRUCTUREISSUER950000FOR95000FOR19 AKESO, INC.G0146B103KYG0146B103206/29/2026Authorize Reissuance of Repurchased SharesCAPITAL STRUCTUREISSUER950000AGAINST95000AGAINST19 ALCON INC.H01301128CH043249246704/30/2026Approval of the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2025CORPORATE GOVERNANCEISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Discharge of the members of the Board of Directors and the members of the Executive CommitteeDIRECTOR ELECTIONSISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Appropriation of earnings and declaration of dividend as per the balance sheet of Alcon Inc. of December 31, 2025CAPITAL STRUCTUREISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Consultative vote on the 2025 Report on Non-Financial MattersOTHER SOCIAL ISSUESISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Consultative vote on the 2025 Compensation ReportSECTION 14A SAY-ON-PAY VOTESISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Binding vote on the maximum aggregate amount of compensation of the Board of Directors for the next term of office, i.e. from the 2026 Annual General Meeting to the 2027 Annual General MeetingCOMPENSATIONISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Binding vote on the maximum aggregate amount of compensation of the Executive Committee for the following financial year, i.e. 2027COMPENSATIONISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of F. Michael Ball (as Member and Chair)DIRECTOR ELECTIONSISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Lynn D. Bleil (as Member)DIRECTOR ELECTIONSISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Arthur Cummings (as Member)DIRECTOR ELECTIONSISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Deborah Di Sanzo (as Member)DIRECTOR ELECTIONSISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of David J. Endicott (as Member)DIRECTOR ELECTIONSISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Thomas Glanzmann (as Member)DIRECTOR ELECTIONSISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of D. Keith Grossman (as Member)DIRECTOR ELECTIONSISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Karen May (as Member)DIRECTOR ELECTIONSISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Ines Pöschel (as Member)DIRECTOR ELECTIONSISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Dieter Spälti (as Member)DIRECTOR ELECTIONSISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Election of R. Scott Herren (as Member)DIRECTOR ELECTIONSISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Thomas Glanzmann as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Karen May as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of Ines Pöschel as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of the independent representative, Hartmann Dreyer, Attorneys-at-lawCORPORATE GOVERNANCEISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026Re-election of the statutory auditors, PricewaterhouseCoopers SA, GenevaAUDIT-RELATEDISSUER662190FOR66219FOR19 ALCON INC.H01301128CH043249246704/30/2026General instruction in case of new agenda items or proposals put forth during the Annual General Meeting (please check one box only) * If you vote FOR, you will be voting in accordance with the recommendation of the Board of Directors. ** If you vote AGAINST, you will be voting against the new agenda items or proposals. *** If you vote ABSTAIN, you will abstain from voting.CORPORATE GOVERNANCEISSUER662190ABSTAIN66219AGAINST19 ALLOGENE THERAPEUTICS, INC.019770106US019770106506/18/2026Election of Directors Deborah MessemerDIRECTOR ELECTIONSISSUER3488770FOR348877FOR19 ALLOGENE THERAPEUTICS, INC.019770106US019770106506/18/2026Election of Directors Vicki Sato, Ph.D.DIRECTOR ELECTIONSISSUER3488770FOR348877FOR19 ALLOGENE THERAPEUTICS, INC.019770106US019770106506/18/2026Election of Directors Owen Witte, M.D.DIRECTOR ELECTIONSISSUER3488770FOR348877FOR19 ALLOGENE THERAPEUTICS, INC.019770106US019770106506/18/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER3488770FOR348877FOR19 ALLOGENE THERAPEUTICS, INC.019770106US019770106506/18/2026To approve, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER34887701 YEAR348877FOR19 ALLOGENE THERAPEUTICS, INC.019770106US019770106506/18/2026To approve an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of common stock from 400,000,000 shares to 800,000,000 shares.CAPITAL STRUCTUREISSUER3488770FOR348877FOR19 ALLOGENE THERAPEUTICS, INC.019770106US019770106506/18/2026To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER3488770FOR348877FOR19 ALUMIS INC022307102US022307102006/30/2026DIRECTOR: James B. TananbaumDIRECTOR ELECTIONSISSUER1016190FOR101619FOR19 ALUMIS INC022307102US022307102006/30/2026DIRECTOR: Lynn Tetrault, J.D.DIRECTOR ELECTIONSISSUER1016190FOR101619FOR19 ALUMIS INC022307102US022307102006/30/2026DIRECTOR: Zhengbin Yao, Ph.D.DIRECTOR ELECTIONSISSUER1016190ABSTAIN101619AGAINST19 ALUMIS INC022307102US022307102006/30/2026To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent auditor for the Company's fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1016190FOR101619FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Wanda M. AustinDIRECTOR ELECTIONSISSUER452820FOR45282FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. BradwayDIRECTOR ELECTIONSISSUER452820FOR45282FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Michael V. DrakeDIRECTOR ELECTIONSISSUER452820FOR45282FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Brian J. DrukerDIRECTOR ELECTIONSISSUER452820FOR45282FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. EckertDIRECTOR ELECTIONSISSUER452820FOR45282FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Greg C. GarlandDIRECTOR ELECTIONSISSUER452820FOR45282FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Charles M. Holley, Jr.DIRECTOR ELECTIONSISSUER452820FOR45282FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. S. Omar IshrakDIRECTOR ELECTIONSISSUER452820FOR45282FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Tyler JacksDIRECTOR ELECTIONSISSUER452820FOR45282FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Mary E. KlotmanDIRECTOR ELECTIONSISSUER452820FOR45282FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Ellen J. KullmanDIRECTOR ELECTIONSISSUER452820FOR45282FOR19 AMGEN INC.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Amy E. MilesDIRECTOR ELECTIONSISSUER452820FOR45282FOR19 AMGEN INC.031162100US031162100905/19/2026Advisory vote to approve our executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER452820FOR45282FOR19 AMGEN INC.031162100US031162100905/19/2026To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER452820FOR45282FOR19 AMGEN INC.031162100US031162100905/19/2026Stockholder proposal to require an independent board chairman.CORPORATE GOVERNANCESECURITY HOLDER452820AGAINST45282FOR19 APOGEE THERAPEUTICS, INC.03770N101US03770N101906/09/2026DIRECTOR: Mark C. McKennaDIRECTOR ELECTIONSISSUER408620FOR40862FOR19 APOGEE THERAPEUTICS, INC.03770N101US03770N101906/09/2026DIRECTOR: Jennifer FoxDIRECTOR ELECTIONSISSUER408620FOR40862FOR19 APOGEE THERAPEUTICS, INC.03770N101US03770N101906/09/2026DIRECTOR: William (BJ) Jones, Jr.DIRECTOR ELECTIONSISSUER408620FOR40862FOR19 APOGEE THERAPEUTICS, INC.03770N101US03770N101906/09/2026Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER408620FOR40862FOR19 APOGEE THERAPEUTICS, INC.03770N101US03770N101906/09/2026Approval, on a non-binding advisory basis, of the compensation of our named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER408620FOR40862FOR19 ARCUS BIOSCIENCES, INC.03969F109US03969F109306/11/2026Election of Directors. Dietmar Berger, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1658050FOR165805FOR19 ARCUS BIOSCIENCES, INC.03969F109US03969F109306/11/2026Election of Directors. David Lacey, M.D.DIRECTOR ELECTIONSISSUER1658050FOR165805FOR19 ARCUS BIOSCIENCES, INC.03969F109US03969F109306/11/2026Election of Directors. Nicole LambertDIRECTOR ELECTIONSISSUER1658050FOR165805FOR19 ARCUS BIOSCIENCES, INC.03969F109US03969F109306/11/2026Election of Directors. Johanna MercierDIRECTOR ELECTIONSISSUER1658050FOR165805FOR19 ARCUS BIOSCIENCES, INC.03969F109US03969F109306/11/2026To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of Arcus Biosciences for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1658050FOR165805FOR19 ARCUS BIOSCIENCES, INC.03969F109US03969F109306/11/2026To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1658050FOR165805FOR19 ARGENX SE04016X101US04016X101905/06/2026The 2025 remuneration report (advisory non-binding voting item)SECTION 14A SAY-ON-PAY VOTESISSUER119330FOR11933FOR19 ARGENX SE04016X101US04016X101905/06/2026Adoption of the 2025 annual accounts (voting item)CORPORATE GOVERNANCEISSUER119330FOR11933FOR19 ARGENX SE04016X101US04016X101905/06/2026Allocation of profits of the Company in the financial year 2025 to the retained earnings of the Company (voting item)CAPITAL STRUCTUREISSUER119330FOR11933FOR19 ARGENX SE04016X101US04016X101905/06/2026Proposal to release the executive director of the Board from liability for his duties carried out in the financial year 2025 (voting item)DIRECTOR ELECTIONSISSUER119330FOR11933FOR19 ARGENX SE04016X101US04016X101905/06/2026Proposal to release the non-executive directors of the Board from liability for their respective duties carried out in the financial year 2025 (voting item)DIRECTOR ELECTIONSISSUER119330FOR11933FOR19 ARGENX SE04016X101US04016X101905/06/2026Appointment of Karen Massey as executive director to the Board, for a four-year term (voting item)DIRECTOR ELECTIONSISSUER119330FOR11933FOR19 ARGENX SE04016X101US04016X101905/06/2026Appointment of Tim Van Hauwermeiren as non-executive director to the Board, for a four-year term (voting item)DIRECTOR ELECTIONSISSUER119330FOR11933FOR19 ARGENX SE04016X101US04016X101905/06/2026Reappointment of Ana Céspedes as non-executive director to the Board, for a four-year term (voting item)DIRECTOR ELECTIONSISSUER119330FOR11933FOR19 ARGENX SE04016X101US04016X101905/06/2026Reappointment of Camilla Sylvest as non-executive director to the Board, for a four-year term (voting item)DIRECTOR ELECTIONSISSUER119330FOR11933FOR19 ARGENX SE04016X101US04016X101905/06/2026Reappointment of Pamela Klein as non-executive director to the Board, for a two-year term (voting item)DIRECTOR ELECTIONSISSUER119330FOR11933FOR19 ARGENX SE04016X101US04016X101905/06/2026Authorization of the board of directors to issue shares and grant rights to subscribe for shares in the share capital of the Company up to a maximum of 10% of the outstanding capital at the date of the general meeting for a period of 18 months from the general meeting and to limit or exclude statutory pre-emptive rights (voting item)CAPITAL STRUCTUREISSUER119330FOR11933FOR19 ARGENX SE04016X101US04016X101905/06/2026Appointment of Ernst & Young Accountants LLP as external auditor of the Company for the 2026 financial year (voting item)AUDIT-RELATEDISSUER119330FOR11933FOR19 ARVINAS, INC.04335A105US04335A105106/24/2026DIRECTOR: Leslie V. Norwalk, Esq.DIRECTOR ELECTIONSISSUER948540FOR94854FOR19 ARVINAS, INC.04335A105US04335A105106/24/2026DIRECTOR: Randy Teel, Ph.D.DIRECTOR ELECTIONSISSUER948540FOR94854FOR19 ARVINAS, INC.04335A105US04335A105106/24/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER948540FOR94854FOR19 ARVINAS, INC.04335A105US04335A105106/24/2026Ratification of the appointment of Deloitte & Touche LLP as the Company's Independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER948540FOR94854FOR19 ASCENDIS PHARMA A S04351P101US04351P101203/23/2026Election of Chair of the Meeting.CORPORATE GOVERNANCEISSUER41660FOR4166FOR19 ASCENDIS PHARMA A S04351P101US04351P101203/23/2026Presentation of Audited Annual Report with Auditor's Statement for Approval and Discharge of the Board of Directors and ManagementCORPORATE GOVERNANCEISSUER41660FOR4166FOR19 ASCENDIS PHARMA A S04351P101US04351P101203/23/2026Resolution on Application of Profits or Covering of Losses as per the Adopted Annual ReportCORPORATE GOVERNANCEISSUER41660FOR4166FOR19 ASCENDIS PHARMA A S04351P101US04351P101203/23/2026Re-Election of Director: Albert ChaDIRECTOR ELECTIONSISSUER41660FOR4166FOR19 ASCENDIS PHARMA A S04351P101US04351P101203/23/2026Re-Election of Director: Lars HoltugDIRECTOR ELECTIONSISSUER41660FOR4166FOR19 ASCENDIS PHARMA A S04351P101US04351P101203/23/2026Re-Election of Director: Jan Møller MikkelsenDIRECTOR ELECTIONSISSUER41660FOR4166FOR19 ASCENDIS PHARMA A S04351P101US04351P101203/23/2026Re-Election of Director: Lisa Jane MorrisonDIRECTOR ELECTIONSISSUER41660FOR4166FOR19 ASCENDIS PHARMA A S04351P101US04351P101203/23/2026Re-Election of Director: William Carl Fairey JrDIRECTOR ELECTIONSISSUER41660FOR4166FOR19 ASCENDIS PHARMA A S04351P101US04351P101203/23/2026Re-Election of Director: Siham ImaniDIRECTOR ELECTIONSISSUER41660FOR4166FOR19 ASCENDIS PHARMA A S04351P101US04351P101203/23/2026Election of Director: Jean-Jacques BienaiméDIRECTOR ELECTIONSISSUER41660FOR4166FOR19 ASCENDIS PHARMA A S04351P101US04351P101203/23/2026Election of State-authorized Public AuditorAUDIT-RELATEDISSUER41660FOR4166FOR19 ASCENDIS PHARMA A S04351P101US04351P101203/23/2026Proposal from the board of directors: Authorization to the Board of Directors to allow the Company to repurchase own shares or American Depositary Shares.CAPITAL STRUCTUREISSUER41660FOR4166FOR19 ASTRAZENECA PLC046353108US046353108911/03/2025To adopt the articles of association produced to the meeting (and for the purpose of identification signed by the Chair of the General Meeting) as the articles of association of the Company in substitution for and to the exclusion of the existing articles of association of the Company, with effect from the conclusion of the meeting.CORPORATE GOVERNANCEISSUER627400FOR62740FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended December 31, 2025CORPORATE GOVERNANCEISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026To confirm the 2025 interim dividendsCAPITAL STRUCTUREISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026To appoint KPMG LLP as AuditorAUDIT-RELATEDISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026To authorize the Directors to agree the remuneration of the AuditorAUDIT-RELATEDCOMPENSATIONISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Election of Director: Michel DemaréDIRECTOR ELECTIONSISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Election of Director: Pascal SoriotDIRECTOR ELECTIONSISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Election of Director: Aradhana SarinDIRECTOR ELECTIONSISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Election of Director: Philip BroadleyDIRECTOR ELECTIONSISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Election of Director: Euan AshleyDIRECTOR ELECTIONSISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Election of Director: Birgit ConixDIRECTOR ELECTIONSISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Election of Director: Rene HaasDIRECTOR ELECTIONSISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Election of Director: Karen KnudsenDIRECTOR ELECTIONSISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Election of Director: Diana LayfieldDIRECTOR ELECTIONSISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Election of Director: Anna ManzDIRECTOR ELECTIONSISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Election of Director: Sheri McCoyDIRECTOR ELECTIONSISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Election of Director: Tony MokDIRECTOR ELECTIONSISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026Election of Director: Marcus WallenbergDIRECTOR ELECTIONSISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended December 31, 2025SECTION 14A SAY-ON-PAY VOTESISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026To renew the authorization to grant awards under the French Appendix 3 of the AstraZeneca Performance Share Plan 2020COMPENSATIONISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026To authorize limited political donationsOTHER SOCIAL ISSUESISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026To authorize the Directors to allot sharesCAPITAL STRUCTUREISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026To authorize the Directors to disapply pre-emption rights1CAPITAL STRUCTUREISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026To authorize the Directors to further disapply pre-emption rights for acquisitions and specified capital investments1CAPITAL STRUCTUREISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026To authorize the Company to purchase its own shares1CAPITAL STRUCTUREISSUER578690FOR57869FOR19 ASTRAZENECA PLCG0593M107GB000989529204/09/2026To reduce the notice period for general meetings1SHAREHOLDER RIGHTS AND DEFENSESISSUER578690FOR57869FOR19 AVALO THERAPEUTICS, INC.05338F306US05338F306406/02/2026DIRECTOR: Michael HeffernanDIRECTOR ELECTIONSISSUER306210FOR30621FOR19 AVALO THERAPEUTICS, INC.05338F306US05338F306406/02/2026DIRECTOR: Garry Neil, M.D.DIRECTOR ELECTIONSISSUER306210FOR30621FOR19 AVALO THERAPEUTICS, INC.05338F306US05338F306406/02/2026DIRECTOR: Rita Jain, M.D.DIRECTOR ELECTIONSISSUER306210FOR30621FOR19 AVALO THERAPEUTICS, INC.05338F306US05338F306406/02/2026DIRECTOR: Aaron KantoffDIRECTOR ELECTIONSISSUER306210FOR30621FOR19 AVALO THERAPEUTICS, INC.05338F306US05338F306406/02/2026DIRECTOR: Gilla Kaplan, Ph.D.DIRECTOR ELECTIONSISSUER306210FOR30621FOR19 AVALO THERAPEUTICS, INC.05338F306US05338F306406/02/2026DIRECTOR: Kevin LindDIRECTOR ELECTIONSISSUER306210FOR30621FOR19 AVALO THERAPEUTICS, INC.05338F306US05338F306406/02/2026DIRECTOR: Samantha TruexDIRECTOR ELECTIONSISSUER306210FOR30621FOR19 AVALO THERAPEUTICS, INC.05338F306US05338F306406/02/2026To approve the Avalo Therapeutics, Inc. Second Amended and Restated 2016 Employee Stock Purchase Plan;COMPENSATIONISSUER306210FOR30621FOR19 AVALO THERAPEUTICS, INC.05338F306US05338F306406/02/2026To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER306210FOR30621FOR19 AVIDITY BIOSCIENCES, INC.05370A108US05370A108802/26/2026To adopt (i) the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Novartis"), Ajax Acquisition Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis, and Avidity Biosciences, Inc., a Delaware corporation (the "Company"), and (ii) the Separation and Distribution Agreement, dated as of October 25, 2025 (the "Separation Agreement"), among the Company, Bryce Therapeutics, Inc., a newly formed Delaware corporation and wholly owned subsidiary of the Company, and which on December 8, 2025, changed its name to Atrium Therapeutics, Inc., and Novartis (with respect to certain sections therein).EXTRAORDINARY TRANSACTIONSISSUER130830FOR13083FOR19 AVIDITY BIOSCIENCES, INC.05370A108US05370A108802/26/2026To adjourn the Special Meeting, if necessary, desirable or appropriate or to solicit additional proxies if, at the time of the Special Meeting, there are an insufficient number of votes in favor of adopting the Merger Agreement and the Separation Agreement.CORPORATE GOVERNANCEISSUER130830FOR13083FOR19 AVIDITY BIOSCIENCES, INC.05370A108US05370A108802/26/2026To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to our named executive officers in connection with the transactions contemplated by the Merger Agreement and the Separation Agreement.SECTION 14A SAY-ON-PAY VOTESISSUER130830FOR13083FOR19 AXSOME THERAPEUTICS, INC.05464T104US05464T104306/05/2026DIRECTOR: Mark SaadDIRECTOR ELECTIONSISSUER287600FOR28760FOR19 AXSOME THERAPEUTICS, INC.05464T104US05464T104306/05/2026DIRECTOR: Susan Mahony, PhD., MBADIRECTOR ELECTIONSISSUER287600FOR28760FOR19 AXSOME THERAPEUTICS, INC.05464T104US05464T104306/05/2026To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER287600FOR28760FOR19 AXSOME THERAPEUTICS, INC.05464T104US05464T104306/05/2026To approve, by non-binding advisory vote, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER287600FOR28760FOR19 BEAM THERAPEUTICS INC.07373V105US07373V105206/03/2026Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029. John EvansDIRECTOR ELECTIONSISSUER768640FOR76864FOR19 BEAM THERAPEUTICS INC.07373V105US07373V105206/03/2026Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029. John Maraganore, Ph.D.DIRECTOR ELECTIONSISSUER768640FOR76864FOR19 BEAM THERAPEUTICS INC.07373V105US07373V105206/03/2026Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029. Christi ShawDIRECTOR ELECTIONSISSUER768640FOR76864FOR19 BEAM THERAPEUTICS INC.07373V105US07373V105206/03/2026Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER768640FOR76864FOR19 BEAM THERAPEUTICS INC.07373V105US07373V105206/03/2026Approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER768640FOR76864FOR19 BICARA THERAPEUTICS INC.055477103US055477103206/09/2026To elect two class II directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. Christopher Bowden, M.D.DIRECTOR ELECTIONSISSUER529580FOR52958FOR19 BICARA THERAPEUTICS INC.055477103US055477103206/09/2026To elect two class II directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. Carolyn Ng, Ph.D.DIRECTOR ELECTIONSISSUER529580FOR52958FOR19 BICARA THERAPEUTICS INC.055477103US055477103206/09/2026To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER529580FOR52958FOR19 BIO-RAD LABORATORIES, INC.090572207US090572207204/21/2026Nominees: Melinda LitherlandDIRECTOR ELECTIONSISSUER176080FOR17608FOR19 BIO-RAD LABORATORIES, INC.090572207US090572207204/21/2026Nominees: Arnold A. PinkstonDIRECTOR ELECTIONSISSUER176080FOR17608FOR19 BIO-RAD LABORATORIES, INC.090572207US090572207204/21/2026Proposal to ratify the selection of KPMG LLP to serve as the Company's independent auditors.AUDIT-RELATEDISSUER176080FOR17608FOR19 BIO-RAD LABORATORIES, INC.090572207US090572207204/21/2026Advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER176080FOR17608FOR19 BIO-RAD LABORATORIES, INC.090572207US090572207204/21/2026Approval of the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan.COMPENSATIONISSUER176080FOR17608FOR19 BIO-RAD LABORATORIES, INC.090572207US090572207204/21/2026Stockholder proposal regarding dual class capital structure.SHAREHOLDER RIGHTS AND DEFENSESCAPITAL STRUCTURESECURITY HOLDER176080FOR17608AGAINST19 BIO-TECHNE CORP09073M104US09073M104510/30/2025To set the number of Directors at nine.CORPORATE GOVERNANCEISSUER1192150FOR119215FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Election of Directors Robert V. BaumgartnerDIRECTOR ELECTIONSISSUER1192150FOR119215FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Election of Directors Julie L. BushmanDIRECTOR ELECTIONSISSUER1192150FOR119215FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Election of Directors Judith KlimovskyDIRECTOR ELECTIONSISSUER1192150FOR119215FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Election of Directors John L. HigginsDIRECTOR ELECTIONSISSUER1192150FOR119215FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Election of Directors Kim KeldermanDIRECTOR ELECTIONSISSUER1192150FOR119215FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Election of Directors Alpna SethDIRECTOR ELECTIONSISSUER1192150FOR119215FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Election of Directors Rupert VesseyDIRECTOR ELECTIONSISSUER1192150FOR119215FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Election of Directors Joseph D. KeeganDIRECTOR ELECTIONSISSUER1192150FOR119215FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Election of Directors Amy HerrDIRECTOR ELECTIONSISSUER1192150FOR119215FOR19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Approve, on an advisory basis, the compensation of our executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1192150AGAINST119215AGAINST19 BIO-TECHNE CORP09073M104US09073M104510/30/2025Ratify the appointment of KPMG, LLP as the Company's independent registered public accounting firm for the 2026 fiscal year.AUDIT-RELATEDISSUER1192150FOR119215FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. Maria C. FreireDIRECTOR ELECTIONSISSUER1342580FOR134258FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. William A. HawkinsDIRECTOR ELECTIONSISSUER1342580FOR134258FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. Susan K. LangerDIRECTOR ELECTIONSISSUER1342580FOR134258FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. Jesus B. MantasDIRECTOR ELECTIONSISSUER1342580FOR134258FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. Lloyd MinorDIRECTOR ELECTIONSISSUER1342580FOR134258FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. Menelas PangalosDIRECTOR ELECTIONSISSUER1342580FOR134258FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. Monish PatolawalaDIRECTOR ELECTIONSISSUER1342580FOR134258FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. Eric K. RowinskyDIRECTOR ELECTIONSISSUER1342580FOR134258FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. Stephen A. SherwinDIRECTOR ELECTIONSISSUER1342580FOR134258FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified. Christopher A. ViehbacherDIRECTOR ELECTIONSISSUER1342580FOR134258FOR19 BIOGEN INC.09062X103US09062X103706/09/2026To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1342580FOR134258FOR19 BIOGEN INC.09062X103US09062X103706/09/2026Say on Pay - To hold an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1342580FOR134258FOR19 BIOHAVEN LTDG1110E107VGG1110E107904/28/2026Election of Directors for a term expiring at the 2029 Annual Meeting of shareholders: Michael T. HeffernanDIRECTOR ELECTIONSISSUER468080FOR46808FOR19 BIOHAVEN LTDG1110E107VGG1110E107904/28/2026Election of Directors for a term expiring at the 2029 Annual Meeting of shareholders: Irina Antonijevic, M.D., Ph.D.DIRECTOR ELECTIONSISSUER468080FOR46808FOR19 BIOHAVEN LTDG1110E107VGG1110E107904/28/2026Election of Directors for a term expiring at the 2029 Annual Meeting of shareholders: Robert J. HuginDIRECTOR ELECTIONSISSUER468080FOR46808FOR19 BIOHAVEN LTDG1110E107VGG1110E107904/28/2026Ratification of appointment of Ernst & Young LLP as independent auditors for fiscal year 2026.AUDIT-RELATEDISSUER468080FOR46808FOR19 BIOHAVEN LTDG1110E107VGG1110E107904/28/2026A non-binding advisory vote on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER468080FOR46808FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Elizabeth M. AndersonDIRECTOR ELECTIONSISSUER316620FOR31662FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Barbara W. BodemDIRECTOR ELECTIONSISSUER316620FOR31662FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Ian T. ClarkDIRECTOR ELECTIONSISSUER316620FOR31662FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Athena CountouriotisDIRECTOR ELECTIONSISSUER316620FOR31662FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Willard DereDIRECTOR ELECTIONSISSUER316620FOR31662FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Mark J. EnyedyDIRECTOR ELECTIONSISSUER316620FOR31662FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Alexander HardyDIRECTOR ELECTIONSISSUER316620FOR31662FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Maykin HoDIRECTOR ELECTIONSISSUER316620FOR31662FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Robert J. HombachDIRECTOR ELECTIONSISSUER316620FOR31662FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026Election of Directors Timothy P. WalbertDIRECTOR ELECTIONSISSUER316620FOR31662FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER316620FOR31662FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER316620FOR31662FOR19 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026To approve an amendment to the Company's 2017 Equity Incentive Plan, as amended.COMPENSATIONISSUER316620FOR31662FOR19 BIONTECH SE09075V102US09075V102605/15/2026Resolution on the appropriation of the balance sheet profit for the 2025 financial yearCAPITAL STRUCTUREISSUER113400FOR11340FOR19 BIONTECH SE09075V102US09075V102605/15/2026Resolution on the approval of the actions of the Management BoardDIRECTOR ELECTIONSISSUER113400FOR11340FOR19 BIONTECH SE09075V102US09075V102605/15/2026Resolution on the approval of the actions of the Supervisory BoardDIRECTOR ELECTIONSISSUER113400FOR11340FOR19 BIONTECH SE09075V102US09075V102605/15/2026Resolution on the appointment of the auditor and the Group auditor for the 2026 financial year and the auditor for any audit or review of interim reportsAUDIT-RELATEDISSUER113400FOR11340FOR19 BIONTECH SE09075V102US09075V102605/15/2026Resolution on the approval of the Compensation ReportSECTION 14A SAY-ON-PAY VOTESISSUER113400AGAINST11340AGAINST19 BIONTECH SE09075V102US09075V102605/15/2026Resolution on the amendment of Section 9 para. 1 of the Articles of Association to increase the size of the Supervisory BoardDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER113400FOR11340FOR19 BIONTECH SE09075V102US09075V102605/15/2026Elections to the Supervisory Board: Mr. Helmut JeggleDIRECTOR ELECTIONSISSUER113400FOR11340FOR19 BIONTECH SE09075V102US09075V102605/15/2026Elections to the Supervisory Board: Prof. Dr. Anja MorawietzDIRECTOR ELECTIONSISSUER113400FOR11340FOR19 BIONTECH SE09075V102US09075V102605/15/2026Elections to the Supervisory Board: Prof. Dr. Rudolf StaudiglDIRECTOR ELECTIONSISSUER113400FOR11340FOR19 BIONTECH SE09075V102US09075V102605/15/2026Elections to the Supervisory Board: Dr. Susanne SchaffertDIRECTOR ELECTIONSISSUER113400FOR11340FOR19 BIONTECH SE09075V102US09075V102605/15/2026Elections to the Supervisory Board: Prof. Dr. Iris Loew-FriedrichDIRECTOR ELECTIONSISSUER113400FOR11340FOR19 BIONTECH SE09075V102US09075V102605/15/2026Resolution on the amendment of Section 16 para. 5 of the Articles of Association to reauthorize the Management Board to provide for the holding of a virtual Annual General MeetingCORPORATE GOVERNANCEISSUER113400FOR11340FOR19 BIONTECH SE09075V102US09075V102605/15/2026Resolution on the cancellation of the existing Authorized Capital 2025 and the creation of new Authorized Capital 2026 with the possibility of excluding subscription rights and corresponding amendment to the Articles of AssociationCAPITAL STRUCTUREISSUER113400FOR11340FOR19 BIONTECH SE09075V102US09075V102605/15/2026Resolution on the approval of the conclusion of a domination and profit and loss transfer agreement between BioNTech SE and BioNTech Discovery GmbHEXTRAORDINARY TRANSACTIONSISSUER113400FOR11340FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. David C. HabigerDIRECTOR ELECTIONSISSUER521030FOR52103FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. Edward J. LudwigDIRECTOR ELECTIONSISSUER521030FOR52103FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. Michael F. MahoneyDIRECTOR ELECTIONSISSUER521030FOR52103FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. Jessica L. MegaDIRECTOR ELECTIONSISSUER521030FOR52103FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. Susan E. MoranoDIRECTOR ELECTIONSISSUER521030FOR52103FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. Cheryl PegusDIRECTOR ELECTIONSISSUER521030FOR52103FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. Cathy R. SmithDIRECTOR ELECTIONSISSUER521030FOR52103FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. Christophe P. WeberDIRECTOR ELECTIONSISSUER521030FOR52103FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. David S. WichmannDIRECTOR ELECTIONSISSUER521030FOR52103FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Proposal to elect ten Directors. Ellen M. ZaneDIRECTOR ELECTIONSISSUER521030FOR52103FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER521030FOR52103FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2026 fiscal year.AUDIT-RELATEDISSUER521030FOR52103FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026To amend our Employee Stock Purchase Plan to increase the number of shares reserved for issuance.COMPENSATIONISSUER521030FOR52103FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026To amend our Certificate of Incorporation to remove supermajority voting provisions.SHAREHOLDER RIGHTS AND DEFENSESISSUER521030FOR52103FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026To amend our Certificate of Incorporation to provide for exculpation of certain officers as permitted by Delaware law.DIRECTOR ELECTIONSISSUER521030FOR52103FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026To amend our Certificate of Incorporation and By-Laws to permit stockholders holding 25% of our common stock to call a special meeting of stockholders.SHAREHOLDER RIGHTS AND DEFENSESISSUER521030FOR52103FOR19 BOSTON SCIENTIFIC CORPORATION101137107US101137107704/30/2026Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting."SHAREHOLDER RIGHTS AND DEFENSESCORPORATE GOVERNANCESECURITY HOLDER521030AGAINST52103FOR19 BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.107924102US107924102206/16/2026To elect two Class I directors to serve until the 2029 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal. Frank McCormick, Ph.D., F.R.S., D.Sc.DIRECTOR ELECTIONSISSUER2636690FOR263669FOR19 BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.107924102US107924102206/16/2026To elect two Class I directors to serve until the 2029 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal. Peter Lebowitz, M.D., Ph.D.DIRECTOR ELECTIONSISSUER2636690FOR263669FOR19 BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.107924102US107924102206/16/2026To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER2636690FOR263669FOR19 BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026DIRECTOR: James C. MomtazeeDIRECTOR ELECTIONSISSUER1367830FOR136783FOR19 BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026DIRECTOR: Frank P. McCormick, PhDDIRECTOR ELECTIONSISSUER1367830FOR136783FOR19 BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026DIRECTOR: Hannah A. Valantine, MDDIRECTOR ELECTIONSISSUER1367830FOR136783FOR19 BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1367830FOR136783FOR19 BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER13678301 YEAR136783FOR19 BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1367830FOR136783FOR19 BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 2,000,000 shares.COMPENSATIONISSUER1367830FOR136783FOR19 BRIGHT MINDS BIOSCIENCES INC.10919W405CA10919W405603/31/2026DIRECTOR: Ian McDonaldDIRECTOR ELECTIONSISSUER319330FOR31933FOR19 BRIGHT MINDS BIOSCIENCES INC.10919W405CA10919W405603/31/2026DIRECTOR: Nils BottlerDIRECTOR ELECTIONSISSUER319330ABSTAIN31933AGAINST19 BRIGHT MINDS BIOSCIENCES INC.10919W405CA10919W405603/31/2026DIRECTOR: Jeremy FryzukDIRECTOR ELECTIONSISSUER319330ABSTAIN31933AGAINST19 BRIGHT MINDS BIOSCIENCES INC.10919W405CA10919W405603/31/2026DIRECTOR: Jan PedersenDIRECTOR ELECTIONSISSUER319330ABSTAIN31933AGAINST19 BRIGHT MINDS BIOSCIENCES INC.10919W405CA10919W405603/31/2026DIRECTOR: David WeinerDIRECTOR ELECTIONSISSUER319330ABSTAIN31933AGAINST19 BRIGHT MINDS BIOSCIENCES INC.10919W405CA10919W405603/31/2026DIRECTOR: Steve FarrDIRECTOR ELECTIONSISSUER319330FOR31933FOR19 BRIGHT MINDS BIOSCIENCES INC.10919W405CA10919W405603/31/2026Appointment of DeVisser Gray LLP, Chartered Professional Accountants, as Auditors of the Company for the ensuing year and authorizing the Directors to fix their remuneration.AUDIT-RELATEDCOMPENSATIONISSUER319330FOR31933FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Peter J. ArduiniDIRECTOR ELECTIONSISSUER1778190FOR177819FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Deepak L. Bhatt, M.D., M.P.H., M.B.A.DIRECTOR ELECTIONSISSUER1778190FOR177819FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Christopher S. Boerner, Ph.D.DIRECTOR ELECTIONSISSUER1778190FOR177819FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Julia A. Haller, M.D.DIRECTOR ELECTIONSISSUER1778190FOR177819FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Manuel Hidalgo Medina, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1778190FOR177819FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Michael R. McMullenDIRECTOR ELECTIONSISSUER1778190FOR177819FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Paula A. PriceDIRECTOR ELECTIONSISSUER1778190FOR177819FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Derica W. RiceDIRECTOR ELECTIONSISSUER1778190FOR177819FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Theodore R. SamuelsDIRECTOR ELECTIONSISSUER1778190FOR177819FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Karen H. Vousden, Ph.D.DIRECTOR ELECTIONSISSUER1778190FOR177819FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Election of Directors Phyllis R. YaleDIRECTOR ELECTIONSISSUER1778190FOR177819FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Advisory Vote to Approve the Compensation of our Named Executive OfficersSECTION 14A SAY-ON-PAY VOTESISSUER1778190FOR177819FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Vote to Approve the Company's 2026 Stock Award and Incentive PlanCOMPENSATIONISSUER1778190FOR177819FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Ratification of the Appointment of an Independent Registered Public Accounting FirmAUDIT-RELATEDISSUER1778190FOR177819FOR19 BRISTOL-MYERS SQUIBB COMPANY110122108US110122108305/05/2026Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent DirectorCORPORATE GOVERNANCESECURITY HOLDER1778190AGAINST177819FOR19 BRUKER CORPORATION116794108US116794108705/21/2026DIRECTOR: John J. (Jack) PhillipsDIRECTOR ELECTIONSISSUER646840FOR64684FOR19 BRUKER CORPORATION116794108US116794108705/21/2026DIRECTOR: Hermann F. Requardt PhDDIRECTOR ELECTIONSISSUER646840FOR64684FOR19 BRUKER CORPORATION116794108US116794108705/21/2026DIRECTOR: Laura A. FrancisDIRECTOR ELECTIONSISSUER646840FOR64684FOR19 BRUKER CORPORATION116794108US116794108705/21/2026Approval on an advisory basis of the 2025 compensation of our named executive officers, as discussed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER646840FOR64684FOR19 BRUKER CORPORATION116794108US116794108705/21/2026Ratification of the appointment of PricewaterhouseCoopers LLP as our Independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER646840FOR64684FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Werner BaumannDIRECTOR ELECTIONSISSUER153830FOR15383FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Frank K. ClyburnDIRECTOR ELECTIONSISSUER153830FOR15383FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Ellen G. CooperDIRECTOR ELECTIONSISSUER153830FOR15383FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. D. Mark DurcanDIRECTOR ELECTIONSISSUER153830FOR15383FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Lon R. GreenbergDIRECTOR ELECTIONSISSUER153830FOR15383FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Lorence H. Kim, M.D.DIRECTOR ELECTIONSISSUER153830FOR15383FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Robert P. MauchDIRECTOR ELECTIONSISSUER153830FOR15383FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Redonda G. Miller, M.D.DIRECTOR ELECTIONSISSUER153830FOR15383FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Dennis M. NallyDIRECTOR ELECTIONSISSUER153830FOR15383FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Lori J. RyerkerkDIRECTOR ELECTIONSISSUER153830FOR15383FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Election of eleven directors. Lauren M. TylerDIRECTOR ELECTIONSISSUER153830FOR15383FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Advisory vote to approve the fiscal 2025 compensation of Cencora, Inc.'s named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER153830FOR15383FOR19 CENCORA, INC.03073E105US03073E105503/05/2026Ratify the appointment of Ernst & Young LLP as Cencora, Inc.'s independent registered public accounting firm for fiscal 2026.AUDIT-RELATEDISSUER153830FOR15383FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Nancy C. AndrewsDIRECTOR ELECTIONSISSUER608830FOR60883FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Steven BargDIRECTOR ELECTIONSISSUER608830FOR60883FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Abraham CeesayDIRECTOR ELECTIONSISSUER608830FOR60883FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Mark EnyedyDIRECTOR ELECTIONSISSUER608830FOR60883FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: James C. FosterDIRECTOR ELECTIONSISSUER608830FOR60883FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Birgit GirshickDIRECTOR ELECTIONSISSUER608830FOR60883FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Paul GravesDIRECTOR ELECTIONSISSUER608830FOR60883FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Reshema Kemps-PolancoDIRECTOR ELECTIONSISSUER608830FOR60883FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: George LladoDIRECTOR ELECTIONSISSUER608830FOR60883FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Martin MackayDIRECTOR ELECTIONSISSUER608830FOR60883FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Craig B. ThompsonDIRECTOR ELECTIONSISSUER608830FOR60883FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Election of Directors: Virginia WilsonDIRECTOR ELECTIONSISSUER608830FOR60883FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Advisory Approval of 2025 Executive Officer CompensationSECTION 14A SAY-ON-PAY VOTESISSUER608830FOR60883FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/20262026 Long-Term Incentive PlanCOMPENSATIONISSUER608830FOR60883FOR19 CHARLES RIVER LABORATORIES INTL., INC.159864107US159864107405/05/2026Ratification of Pricewaterhousecoopers LLC as independent registered public accounting firm for 2026AUDIT-RELATEDISSUER608830FOR60883FOR19 COGENT BIOSCIENCES, INC.19240Q201US19240Q201206/09/2026DIRECTOR: Dr. Chris CainDIRECTOR ELECTIONSISSUER2626940FOR262694FOR19 COGENT BIOSCIENCES, INC.19240Q201US19240Q201206/09/2026DIRECTOR: Arlene M. MorrisDIRECTOR ELECTIONSISSUER2626940FOR262694FOR19 COGENT BIOSCIENCES, INC.19240Q201US19240Q201206/09/2026DIRECTOR: Todd ShegogDIRECTOR ELECTIONSISSUER2626940FOR262694FOR19 COGENT BIOSCIENCES, INC.19240Q201US19240Q201206/09/2026Ratification of the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER2626940FOR262694FOR19 COGENT BIOSCIENCES, INC.19240Q201US19240Q201206/09/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2626940FOR262694FOR19 CORVUS PHARMACEUTICALS, INC.221015100US221015100506/11/2026To elect two Class I Directors with terms to expire at the 2029 annual meeting of stockholders: Richard A. Miller, M.DDIRECTOR ELECTIONSISSUER247710FOR24771FOR19 CORVUS PHARMACEUTICALS, INC.221015100US221015100506/11/2026To elect two Class I Directors with terms to expire at the 2029 annual meeting of stockholders: Linda S. Grais, M.D. J.DDIRECTOR ELECTIONSISSUER247710WITHHOLD24771AGAINST19 CORVUS PHARMACEUTICALS, INC.221015100US221015100506/11/2026To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER247710FOR24771FOR19 CORVUS PHARMACEUTICALS, INC.221015100US221015100506/11/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER247710FOR24771FOR19 CYTOKINETICS, INCORPORATED23282W605US23282W605705/27/2026Election of Class I Directors for terms expiring in 2029. Edward M. Kaye, M.D.DIRECTOR ELECTIONSISSUER170610FOR17061FOR19 CYTOKINETICS, INCORPORATED23282W605US23282W605705/27/2026Election of Class I Directors for terms expiring in 2029. Wendell Wierenga, Ph.D.DIRECTOR ELECTIONSISSUER170610FOR17061FOR19 CYTOKINETICS, INCORPORATED23282W605US23282W605705/27/2026Election of Class I Directors for terms expiring in 2029. Nancy J. WysenskiDIRECTOR ELECTIONSISSUER170610FOR17061FOR19 CYTOKINETICS, INCORPORATED23282W605US23282W605705/27/2026To approve the amendment and restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance thereunder by 1,000,000 shares of common stock.COMPENSATIONISSUER170610FOR17061FOR19 CYTOKINETICS, INCORPORATED23282W605US23282W605705/27/2026To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER170610FOR17061FOR19 CYTOKINETICS, INCORPORATED23282W605US23282W605705/27/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER170610FOR17061FOR19 CYTOMX THERAPEUTICS, INC.23284F105US23284F105706/17/2026To elect two directors with terms to expire at the 2029 Annual Meeting of Stockholders; Matthew P. YoungDIRECTOR ELECTIONSISSUER2157480FOR215748FOR19 CYTOMX THERAPEUTICS, INC.23284F105US23284F105706/17/2026To elect two directors with terms to expire at the 2029 Annual Meeting of Stockholders; Elaine V. Jones, Ph.D.DIRECTOR ELECTIONSISSUER2157480FOR215748FOR19 CYTOMX THERAPEUTICS, INC.23284F105US23284F105706/17/2026To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER2157480FOR215748FOR19 CYTOMX THERAPEUTICS, INC.23284F105US23284F105706/17/2026To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 shares to 600,000,000 shares;CAPITAL STRUCTUREISSUER2157480FOR215748FOR19 CYTOMX THERAPEUTICS, INC.23284F105US23284F105706/17/2026To approve an amendment to our Amended and Restated 2015 Equity Incentive Plan;COMPENSATIONISSUER2157480FOR215748FOR19 CYTOMX THERAPEUTICS, INC.23284F105US23284F105706/17/2026To approve an amendment to our Amended and Restated Employee Stock Purchase Plan;COMPENSATIONISSUER2157480FOR215748FOR19 CYTOMX THERAPEUTICS, INC.23284F105US23284F105706/17/2026To approve, on a nonbinding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders; andSECTION 14A SAY-ON-PAY VOTESISSUER2157480FOR215748FOR19 CYTOMX THERAPEUTICS, INC.23284F105US23284F105706/17/2026To hold a non-binding advisory vote on the frequency of future advisory votes by stockholders on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER21574801 YEAR215748FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Approve Appropriation of SurplusCAPITAL STRUCTUREISSUER939000FOR93900FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Okuzawa, HiroyukiDIRECTOR ELECTIONSISSUER939000FOR93900FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Matsumoto, TakashiDIRECTOR ELECTIONSISSUER939000FOR93900FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Ueno, ShizukoDIRECTOR ELECTIONSISSUER939000FOR93900FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Joseph Kenneth KellerDIRECTOR ELECTIONSISSUER939000FOR93900FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Komatsu, YasuhiroDIRECTOR ELECTIONSISSUER939000FOR93900FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Nishii, TakaakiDIRECTOR ELECTIONSISSUER939000FOR93900FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Homma, YoDIRECTOR ELECTIONSISSUER939000FOR93900FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Watanabe, AkihiroDIRECTOR ELECTIONSISSUER939000FOR93900FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Kinoshita, ReikoDIRECTOR ELECTIONSISSUER939000FOR93900FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Director Stuart MackeyDIRECTOR ELECTIONSISSUER939000FOR93900FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Corporate Auditor Murata, TakashiCORPORATE GOVERNANCEISSUER939000FOR93900FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Appoint a Corporate Auditor Tago, SayuriCORPORATE GOVERNANCEISSUER939000FOR93900FOR19 DAIICHI SANKYO COMPANY,LIMITEDJ11257102JP347535000906/22/2026Approve Details of the Performance-based Stock Compensation to be received by DirectorsCOMPENSATIONISSUER939000FOR93900FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Rainer M. BlairDIRECTOR ELECTIONSISSUER601060FOR60106FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Feroz DewanDIRECTOR ELECTIONSISSUER601060FOR60106FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Linda FillerDIRECTOR ELECTIONSISSUER601060FOR60106FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Charles W. LamannaDIRECTOR ELECTIONSISSUER601060FOR60106FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Teri L. ListDIRECTOR ELECTIONSISSUER601060FOR60106FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Mitchell P. RalesDIRECTOR ELECTIONSISSUER601060FOR60106FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Steven M. RalesDIRECTOR ELECTIONSISSUER601060FOR60106FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. A. Shane SandersDIRECTOR ELECTIONSISSUER601060FOR60106FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Alan G. SpoonDIRECTOR ELECTIONSISSUER601060FOR60106FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Raymond C. Stevens, Ph.DDIRECTOR ELECTIONSISSUER601060FOR60106FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Elias A. Zerhouni, MDDIRECTOR ELECTIONSISSUER601060FOR60106FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To ratify the selection of Ernst & Young LLP as Danaher's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER601060FOR60106FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To approve on an advisory basis the Company's named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER601060FOR60106FOR19 DANAHER CORPORATION235851102US235851102805/05/2026To approve the Company's Amended and Restated Omnibus Incentive Plan.COMPENSATIONISSUER601060FOR60106FOR19 DENALI THERAPEUTICS INC.24823R105US24823R105906/03/2026DIRECTOR: Jennifer CookDIRECTOR ELECTIONSISSUER5041527638FOR50415FOR19 DENALI THERAPEUTICS INC.24823R105US24823R105906/03/2026DIRECTOR: David Schenkein, M.D.DIRECTOR ELECTIONSISSUER5041527638FOR50415FOR19 DENALI THERAPEUTICS INC.24823R105US24823R105906/03/2026DIRECTOR: Ryan Watts, Ph.D.DIRECTOR ELECTIONSISSUER5041527638FOR50415FOR19 DENALI THERAPEUTICS INC.24823R105US24823R105906/03/2026Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER5041527638FOR50415FOR19 DENALI THERAPEUTICS INC.24823R105US24823R105906/03/2026Advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER5041527638FOR50415FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Steven AltmanDIRECTOR ELECTIONSISSUER951260FOR95126FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Dr. Euan AshleyDIRECTOR ELECTIONSISSUER951260FOR95126FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Nicholas AugustinosDIRECTOR ELECTIONSISSUER951260FOR95126FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Richard CollinsDIRECTOR ELECTIONSISSUER951260FOR95126FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Rimma DriscollDIRECTOR ELECTIONSISSUER951260FOR95126FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Mark FolettaDIRECTOR ELECTIONSISSUER951260FOR95126FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Renée GaláDIRECTOR ELECTIONSISSUER951260FOR95126FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Bridgette HellerDIRECTOR ELECTIONSISSUER951260FOR95126FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Jacob LeachDIRECTOR ELECTIONSISSUER951260FOR95126FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Kyle MaladyDIRECTOR ELECTIONSISSUER951260FOR95126FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Rick OsterlohDIRECTOR ELECTIONSISSUER951260FOR95126FOR19 DEXCOM, INC.252131107US252131107405/27/2026To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Kevin SayerDIRECTOR ELECTIONSISSUER951260FOR95126FOR19 DEXCOM, INC.252131107US252131107405/27/2026To ratify the selection by the Audit Committee of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER951260FOR95126FOR19 DEXCOM, INC.252131107US252131107405/27/2026To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER951260FOR95126FOR19 DIANTHUS THERAPEUTICS, INC.252828108US252828108005/21/2026To elect Class II directors, to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Sujay KangoDIRECTOR ELECTIONSISSUER622790FOR62279FOR19 DIANTHUS THERAPEUTICS, INC.252828108US252828108005/21/2026To elect Class II directors, to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Anne McGeorgeDIRECTOR ELECTIONSISSUER622790FOR62279FOR19 DIANTHUS THERAPEUTICS, INC.252828108US252828108005/21/2026To elect Class II directors, to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Jonathan Violin, Ph.D.DIRECTOR ELECTIONSISSUER622790FOR62279FOR19 DIANTHUS THERAPEUTICS, INC.252828108US252828108005/21/2026To approve, on an advisory basis, the compensation paid to our named executive officers; andSECTION 14A SAY-ON-PAY VOTESISSUER622790FOR62279FOR19 DIANTHUS THERAPEUTICS, INC.252828108US252828108005/21/2026To ratify the appointment of Deloitte & Touche, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER622790FOR62279FOR19 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified. David LubnerDIRECTOR ELECTIONSISSUER809310FOR80931FOR19 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified. Brian PosnerDIRECTOR ELECTIONSISSUER809310FOR80931FOR19 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified. Jason RhodesDIRECTOR ELECTIONSISSUER809310WITHHOLD80931AGAINST19 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To vote, on an advisory basis, to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER809310FOR80931FOR19 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To approve an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares.CAPITAL STRUCTUREISSUER809310FOR80931FOR19 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To approve an amendment to our Restated Certificate of Incorporation to provide for officer exculpation.DIRECTOR ELECTIONSISSUER809310FOR80931FOR19 DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER809310FOR80931FOR19 EDGEWISE THERAPEUTICS INC28036F105US28036F105706/04/2026DIRECTOR: Laura BregeDIRECTOR ELECTIONSISSUER891510FOR89151FOR19 EDGEWISE THERAPEUTICS INC28036F105US28036F105706/04/2026DIRECTOR: Badreddin Edris, Ph.D.DIRECTOR ELECTIONSISSUER891510ABSTAIN89151AGAINST19 EDGEWISE THERAPEUTICS INC28036F105US28036F105706/04/2026DIRECTOR: Jonathan Root, M.D.DIRECTOR ELECTIONSISSUER891510ABSTAIN89151AGAINST19 EDGEWISE THERAPEUTICS INC28036F105US28036F105706/04/2026Ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER891510FOR89151FOR19 EDGEWISE THERAPEUTICS INC28036F105US28036F105706/04/2026Conduct an advisory vote on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER891510FOR89151FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Election of Directors Leslie C. DavisDIRECTOR ELECTIONSISSUER1804020FOR180402FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Election of Directors David T. Feinberg, MDDIRECTOR ELECTIONSISSUER1804020FOR180402FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Election of Directors Kieran T. GallahueDIRECTOR ELECTIONSISSUER1804020FOR180402FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Election of Directors Leslie S. HeiszDIRECTOR ELECTIONSISSUER1804020FOR180402FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Election of Directors Paul A. LaVioletteDIRECTOR ELECTIONSISSUER1804020FOR180402FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Election of Directors Steven R. LorangerDIRECTOR ELECTIONSISSUER1804020FOR180402FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Election of Directors Ramona SequeiraDIRECTOR ELECTIONSISSUER1804020FOR180402FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Election of Directors Nicholas J. ValerianiDIRECTOR ELECTIONSISSUER1804020FOR180402FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Election of Directors Bernard ZovighianDIRECTOR ELECTIONSISSUER1804020FOR180402FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Advisory Vote to Approve Named Executive Officer CompensationSECTION 14A SAY-ON-PAY VOTESISSUER1804020FOR180402FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Ratification of Appointment of Independent Registered Public Accounting FirmAUDIT-RELATEDISSUER1804020FOR180402FOR19 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Approval of the Amended and Restated Long-Term Stock Incentive Compensation ProgramCOMPENSATIONISSUER1804020FOR180402FOR19 EISAI CO.,LTD.J12852117JP316040000206/17/2026Appoint a Director Naito, HaruoDIRECTOR ELECTIONSISSUER3049000FOR304900FOR19 EISAI CO.,LTD.J12852117JP316040000206/17/2026Appoint a Director Ike, FumihikoDIRECTOR ELECTIONSISSUER3049000FOR304900FOR19 EISAI CO.,LTD.J12852117JP316040000206/17/2026Appoint a Director Kato, HiroyukiDIRECTOR ELECTIONSISSUER3049000FOR304900FOR19 EISAI CO.,LTD.J12852117JP316040000206/17/2026Appoint a Director Richard ThornleyDIRECTOR ELECTIONSISSUER3049000FOR304900FOR19 EISAI CO.,LTD.J12852117JP316040000206/17/2026Appoint a Director Moriyama, ToruDIRECTOR ELECTIONSISSUER3049000FOR304900FOR19 EISAI CO.,LTD.J12852117JP316040000206/17/2026Appoint a Director Yasuda, YukoDIRECTOR ELECTIONSISSUER3049000FOR304900FOR19 EISAI CO.,LTD.J12852117JP316040000206/17/2026Appoint a Director Kanai, TakujiDIRECTOR ELECTIONSISSUER3049000FOR304900FOR19 EISAI CO.,LTD.J12852117JP316040000206/17/2026Appoint a Director Takahashi, KentaDIRECTOR ELECTIONSISSUER3049000FOR304900FOR19 EISAI CO.,LTD.J12852117JP316040000206/17/2026Appoint a Director Okada, YasushiDIRECTOR ELECTIONSISSUER3049000FOR304900FOR19 EISAI CO.,LTD.J12852117JP316040000206/17/2026Appoint a Director Ueda, RyokoDIRECTOR ELECTIONSISSUER3049000FOR304900FOR19 EISAI CO.,LTD.J12852117JP316040000206/17/2026Appoint a Director Kawana, KoichiDIRECTOR ELECTIONSISSUER3049000FOR304900FOR19 EISAI CO.,LTD.J12852117JP316040000206/17/2026Appoint a Director Toyoda, YukoDIRECTOR ELECTIONSISSUER3049000FOR304900FOR19 ELANCO ANIMAL HEALTH INCORPORATED28414H103US28414H103205/21/2026Election of two Class I director nominees and three Class II director nominees: Kapila AnandDIRECTOR ELECTIONSISSUER17001140498FOR170011FOR19 ELANCO ANIMAL HEALTH INCORPORATED28414H103US28414H103205/21/2026Election of two Class I director nominees and three Class II director nominees: Paul HerendeenDIRECTOR ELECTIONSISSUER17001140498FOR170011FOR19 ELANCO ANIMAL HEALTH INCORPORATED28414H103US28414H103205/21/2026Election of two Class I director nominees and three Class II director nominees: Michael HarringtonDIRECTOR ELECTIONSISSUER17001140498FOR170011FOR19 ELANCO ANIMAL HEALTH INCORPORATED28414H103US28414H103205/21/2026Election of two Class I director nominees and three Class II director nominees: Lawrence KurziusDIRECTOR ELECTIONSISSUER17001140498FOR170011FOR19 ELANCO ANIMAL HEALTH INCORPORATED28414H103US28414H103205/21/2026Election of two Class I director nominees and three Class II director nominees: Kirk McDonaldDIRECTOR ELECTIONSISSUER17001140498FOR170011FOR19 ELANCO ANIMAL HEALTH INCORPORATED28414H103US28414H103205/21/2026Ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER17001140498FOR170011FOR19 ELANCO ANIMAL HEALTH INCORPORATED28414H103US28414H103205/21/2026Advisory vote on the compensation of the company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER17001140498FOR170011FOR19 ENANTA PHARMACEUTICALS, INC.29251M106US29251M106203/11/2026To elect two Class I directors to serve until the 2029 Annual Meeting of Stockholders or until their respective successors are elected and qualified. Bruce L.A. Carter, Ph.D.DIRECTOR ELECTIONSISSUER697290FOR69729FOR19 ENANTA PHARMACEUTICALS, INC.29251M106US29251M106203/11/2026To elect two Class I directors to serve until the 2029 Annual Meeting of Stockholders or until their respective successors are elected and qualified. Jay R. Luly, Ph.D.DIRECTOR ELECTIONSISSUER697290FOR69729FOR19 ENANTA PHARMACEUTICALS, INC.29251M106US29251M106203/11/2026To approve an amendment to our 2019 Equity Incentive Plan.COMPENSATIONISSUER697290FOR69729FOR19 ENANTA PHARMACEUTICALS, INC.29251M106US29251M106203/11/2026To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER697290FOR69729FOR19 ENANTA PHARMACEUTICALS, INC.29251M106US29251M106203/11/2026To ratify the appointment of PricewaterhouseCoopers LLP as Enanta's independent registered public accounting firm for the 2026 fiscal year.AUDIT-RELATEDISSUER697290FOR69729FOR19 ENLIVEN THERAPEUTICS, INC.29337E102US29337E102906/09/2026To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal. Richard Fair, M.B.A.DIRECTOR ELECTIONSISSUER548850FOR54885FOR19 ENLIVEN THERAPEUTICS, INC.29337E102US29337E102906/09/2026To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal. Lori Kunkel, M.D.DIRECTOR ELECTIONSISSUER548850FOR54885FOR19 ENLIVEN THERAPEUTICS, INC.29337E102US29337E102906/09/2026To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER548850FOR54885FOR19 ENLIVEN THERAPEUTICS, INC.29337E102US29337E102906/09/2026To amend our amended and restated certificate of incorporation, as amended, to increase our authorized shares of common stock from 100,000,000 shares to 200,000,000 shares.CAPITAL STRUCTUREISSUER548850FOR54885FOR19 ENLIVEN THERAPEUTICS, INC.29337E102US29337E102906/09/2026To approve, in an advisory (non-binding) vote, the compensation of our named executive officers as disclosed in our proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER548850FOR54885FOR19 ENLIVEN THERAPEUTICS, INC.29337E102US29337E102906/09/2026To approve, in an advisory (non-binding) vote, the frequency of future stockholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER5488501 YEAR54885FOR19 ERASCA, INC.29479A108US29479A108806/26/2026To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified Alexander W. CasdinDIRECTOR ELECTIONSISSUER1592400FOR159240FOR19 ERASCA, INC.29479A108US29479A108806/26/2026To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified Julie Hambleton, M.D.DIRECTOR ELECTIONSISSUER1592400FOR159240FOR19 ERASCA, INC.29479A108US29479A108806/26/2026To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified Michael D. Varney, Ph.D.DIRECTOR ELECTIONSISSUER1592400FOR159240FOR19 ERASCA, INC.29479A108US29479A108806/26/2026To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026AUDIT-RELATEDISSUER1592400FOR159240FOR19 EXACT SCIENCES CORPORATION30063P105US30063P105702/20/2026Proposal to adopt the Agreement and Plan of Merger, dated as of November 19, 2025, as it may be amended from time to time (the "Merger Agreement"), by and among Exact Sciences Corporation, Abbott Laboratories and Badger Merger Sub I, Inc. (the "Merger Agreement Proposal").EXTRAORDINARY TRANSACTIONSISSUER2294550FOR229455FOR19 EXACT SCIENCES CORPORATION30063P105US30063P105702/20/2026Proposal to approve, on an advisory (nonbinding) basis, the compensation that may be paid or become payable to Exact Sciences Corporation's named executive officers that is based on or otherwise related to the Merger Agreement and the transactions contemplated by the Merger Agreement (the "Compensation Proposal").SECTION 14A SAY-ON-PAY VOTESISSUER2294550FOR229455FOR19 EXACT SCIENCES CORPORATION30063P105US30063P105702/20/2026Proposal to approve any adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the Special Meeting to approve the Merger Agreement Proposal (the "Adjournment Proposal").CORPORATE GOVERNANCEISSUER2294550FOR229455FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. Mary C. Beckerle, Ph.D.DIRECTOR ELECTIONSISSUER2101760FOR210176FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. S. Gail Eckhardt, M.D.DIRECTOR ELECTIONSISSUER2101760FOR210176FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. Maria C. Freire, Ph.D.DIRECTOR ELECTIONSISSUER2101760FOR210176FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. Tomas J. HeymanDIRECTOR ELECTIONSISSUER2101760FOR210176FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. David E. JohnsonDIRECTOR ELECTIONSISSUER2101760FOR210176FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. Michael M. Morrissey, Ph.D.DIRECTOR ELECTIONSISSUER2101760FOR210176FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. Robert L. Oliver, Jr.DIRECTOR ELECTIONSISSUER2101760FOR210176FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. Stelios Papadopoulos, Ph.D.DIRECTOR ELECTIONSISSUER2101760FOR210176FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. George Poste, DVM, Ph.D., FRSDIRECTOR ELECTIONSISSUER2101760FOR210176FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. Julie Anne SmithDIRECTOR ELECTIONSISSUER2101760FOR210176FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders. Jack L. WyszomierskiDIRECTOR ELECTIONSISSUER2101760FOR210176FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis' independent registered public accounting firm for the fiscal year ending January 1, 2027.AUDIT-RELATEDISSUER2101760FOR210176FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To amend and restate the Exelixis, Inc. 2017 Equity Incentive Plan to, among other things, increase the number of shares authorized for issuance by 2,000,000 shares.COMPENSATIONISSUER2101760FOR210176FOR19 EXELIXIS, INC.30161Q104US30161Q104005/26/2026To approve, on an advisory basis, the compensation of Exelixis' named executive officers, as disclosed in the accompanying Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER2101760FOR210176FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026DIRECTOR: Göran Ando, M.D.DIRECTOR ELECTIONSISSUER750920FOR75092FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026DIRECTOR: Jay S. Duker, M.D.DIRECTOR ELECTIONSISSUER750920FOR75092FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026DIRECTOR: John B. Landis, Ph.D.DIRECTOR ELECTIONSISSUER750920FOR75092FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026DIRECTOR: Wendy DiCiccoDIRECTOR ELECTIONSISSUER750920FOR75092FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026DIRECTOR: Karen ZaderejDIRECTOR ELECTIONSISSUER750920FOR75092FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026DIRECTOR: Stuart DutyDIRECTOR ELECTIONSISSUER750920FOR75092FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026DIRECTOR: Fred HassanDIRECTOR ELECTIONSISSUER750920FOR75092FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026DIRECTOR: Reginald Sanders, M.D.DIRECTOR ELECTIONSISSUER750920FOR75092FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026To approve Amendment No. 3 to the EyePoint, Inc. 2023 Long-Term Incentive Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 4,900,000 shares.COMPENSATIONISSUER750920FOR75092FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER750920FOR75092FOR19 EYEPOINT, INC.30233G209US30233G209306/18/2026To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER750920FOR75092FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER294820FOR29482FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Approve Non-Financial ReportOTHER SOCIAL ISSUESISSUER294820FOR29482FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Approve Remuneration Report (Non-Binding)SECTION 14A SAY-ON-PAY VOTESISSUER294820AGAINST29482AGAINST19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Approve Allocation of Income and Dividends of CHF 0.35 per Share from Capital Contribution ReservesCAPITAL STRUCTUREISSUER294820FOR29482FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Approve Discharge of Board and Senior ManagementDIRECTOR ELECTIONSISSUER294820FOR29482FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reelect Thomas Ebeling as Director and Board ChairDIRECTOR ELECTIONSISSUER294820FOR29482FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reelect Daniel Browne as DirectorDIRECTOR ELECTIONSISSUER294820FOR29482FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reelect Maria Hilado as DirectorDIRECTOR ELECTIONSISSUER294820FOR29482FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reelect Karen Ling as DirectorDIRECTOR ELECTIONSISSUER294820FOR29482FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reelect Roberto Marques as DirectorDIRECTOR ELECTIONSISSUER294820FOR29482FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reelect Sherilyn McCoy as DirectorDIRECTOR ELECTIONSISSUER294820FOR29482FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reelect Flemming Ornskov as DirectorDIRECTOR ELECTIONSISSUER294820FOR29482FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Elect Harry Kirsch as DirectorDIRECTOR ELECTIONSISSUER294820FOR29482FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Elect Samuel du Retail as DirectorDIRECTOR ELECTIONSISSUER294820AGAINST29482NONE19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Elect Delphine Viguier-Hovasse as DirectorDIRECTOR ELECTIONSISSUER294820AGAINST29482NONE19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reappoint Karen Ling as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER294820FOR29482FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reappoint Thomas Ebeling as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER294820FOR29482FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Reappoint Roberto Marques as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER294820FOR29482FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Approve Remuneration of Directors in the Amount of CHF 3.2 MillionCOMPENSATIONISSUER294820FOR29482FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Approve Remuneration of Executive Committee in the Amount of CHF 31.2 MillionCOMPENSATIONISSUER294820AGAINST29482AGAINST19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Designate Altenburger Ltd as Independent ProxyCORPORATE GOVERNANCEISSUER294820FOR29482FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Ratify KPMG AG as AuditorsAUDIT-RELATEDISSUER294820FOR29482FOR19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Transact Other Business (Voting)CORPORATE GOVERNANCEISSUER294820ABSTAIN29482AGAINST19 GALDERMA GROUP AGH3301B107CH133539272104/22/2026Share Re-registration ConsentCORPORATE GOVERNANCEISSUER294820FOR29482FOR19 GENMAB A/SK3967W102DK001027220203/19/2026Accept Financial Statements and Statutory Reports; Approve Discharge of Management and BoardCORPORATE GOVERNANCEISSUER581590FOR58159FOR19 GENMAB A/SK3967W102DK001027220203/19/2026Approve Allocation of Income and Omission of DividendsCAPITAL STRUCTUREISSUER581590FOR58159FOR19 GENMAB A/SK3967W102DK001027220203/19/2026Approve Remuneration Report (Advisory Vote)SECTION 14A SAY-ON-PAY VOTESISSUER581590FOR58159FOR19 GENMAB A/SK3967W102DK001027220203/19/2026Reelect Deirdre P. Connelly as DirectorDIRECTOR ELECTIONSISSUER581590ABSTAIN58159AGAINST19 GENMAB A/SK3967W102DK001027220203/19/2026Reelect Pernille Erenbjerg as DirectorDIRECTOR ELECTIONSISSUER581590FOR58159FOR19 GENMAB A/SK3967W102DK001027220203/19/2026Reelect Rolf Hoffmann as DirectorDIRECTOR ELECTIONSISSUER581590FOR58159FOR19 GENMAB A/SK3967W102DK001027220203/19/2026Reelect Elizabeth O'Farrell as DirectorDIRECTOR ELECTIONSISSUER581590FOR58159FOR19 GENMAB A/SK3967W102DK001027220203/19/2026Reelect Paolo Paoletti as DirectorDIRECTOR ELECTIONSISSUER581590FOR58159FOR19 GENMAB A/SK3967W102DK001027220203/19/2026Reelect Anders Gersel Pedersen as DirectorDIRECTOR ELECTIONSISSUER581590FOR58159FOR19 GENMAB A/SK3967W102DK001027220203/19/2026Ratify Deloitte as Auditors; Appoint Deloitte as Auditor for Sustainability ReportingAUDIT-RELATEDISSUER581590FOR58159FOR19 GENMAB A/SK3967W102DK001027220203/19/2026Approve Remuneration of Directors in the Amount of DKK 1.2 Million for Chair, DKK 900,000 for Vice Chair, and DKK 600,000 for Other Directors; Approve Remuneration for Committee WorkCOMPENSATIONISSUER581590FOR58159FOR19 GENMAB A/SK3967W102DK001027220203/19/2026Approve DKK 1.9 Million Reduction in Share Capital via Share CancellationCAPITAL STRUCTUREISSUER581590FOR58159FOR19 GENMAB A/SK3967W102DK001027220203/19/2026Authorize Editorial Changes to Adopted Resolutions in Connection with Registration with Danish AuthoritiesCORPORATE GOVERNANCEISSUER581590FOR58159FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. Jacqueline K. Barton, Ph.D.DIRECTOR ELECTIONSISSUER1977170FOR197717FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. Jeffrey A. Bluestone, Ph.D.DIRECTOR ELECTIONSISSUER1977170FOR197717FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. Sandra J. Horning, M.D.DIRECTOR ELECTIONSISSUER1977170FOR197717FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. Kelly A. KramerDIRECTOR ELECTIONSISSUER1977170FOR197717FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. Ted W. Love, M.D.DIRECTOR ELECTIONSISSUER1977170FOR197717FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. Harish ManwaniDIRECTOR ELECTIONSISSUER1977170FOR197717FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. Daniel P. O'DayDIRECTOR ELECTIONSISSUER1977170FOR197717FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. Javier J. RodriguezDIRECTOR ELECTIONSISSUER1977170FOR197717FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. Anthony WeltersDIRECTOR ELECTIONSISSUER1977170FOR197717FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1977170FOR197717FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1977170FOR197717FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To approve the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan.COMPENSATIONISSUER1977170FOR197717FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting.CORPORATE GOVERNANCESECURITY HOLDER1977170AGAINST197717FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting.OTHER SOCIAL ISSUESSECURITY HOLDER1977170AGAINST197717FOR19 GILEAD SCIENCES, INC.375558103US375558103604/30/2026To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics, if properly presented at the Annual Meeting.CORPORATE GOVERNANCEDIVERSITY, EQUITY, AND INCLUSIONSECURITY HOLDER1977170AGAINST197717FOR19 GLAUKOS CORPORATION377322102US377322102905/28/2026DIRECTOR: Denice M. TorresDIRECTOR ELECTIONSISSUER120980FOR12098FOR19 GLAUKOS CORPORATION377322102US377322102905/28/2026DIRECTOR: Aimee S. WeisnerDIRECTOR ELECTIONSISSUER120980FOR12098FOR19 GLAUKOS CORPORATION377322102US377322102905/28/2026Approval, on an advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER120980FOR12098FOR19 GLAUKOS CORPORATION377322102US377322102905/28/2026Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER120980FOR12098FOR19 GOSSAMER BIO, INC.38341P102US38341P102106/04/2026Election of Class II Directors Russell CoxDIRECTOR ELECTIONSISSUER60095100FOR60095FOR19 GOSSAMER BIO, INC.38341P102US38341P102106/04/2026Election of Class II Directors Faheem HasnainDIRECTOR ELECTIONSISSUER60095100FOR60095FOR19 GOSSAMER BIO, INC.38341P102US38341P102106/04/2026Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accountants for the year ending December 31, 2026.AUDIT-RELATEDISSUER60095100FOR60095FOR19 GOSSAMER BIO, INC.38341P102US38341P102106/04/2026Approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER60095100FOR60095FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Approve Remuneration ReportSECTION 14A SAY-ON-PAY VOTESISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Amend Remuneration PolicyCOMPENSATIONCORPORATE GOVERNANCEISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Elect Luke Miels as DirectorDIRECTOR ELECTIONSISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Re-elect Sir Jonathan Symonds as DirectorDIRECTOR ELECTIONSISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Re-elect Julie Brown as DirectorDIRECTOR ELECTIONSISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Re-elect Elizabeth Anderson as DirectorDIRECTOR ELECTIONSISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Re-elect Charles Bancroft as DirectorDIRECTOR ELECTIONSISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Re-elect Hal Barron as DirectorDIRECTOR ELECTIONSISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Re-elect Anne Beal as DirectorDIRECTOR ELECTIONSISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Re-elect Wendy Becker as DirectorDIRECTOR ELECTIONSISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Re-elect Harry Dietz as DirectorDIRECTOR ELECTIONSISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Re-elect Jeannie Lee as DirectorDIRECTOR ELECTIONSISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Re-elect Gavin Screaton as DirectorDIRECTOR ELECTIONSISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Re-elect Vishal Sikka as DirectorDIRECTOR ELECTIONSISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Reappoint Deloitte LLP as AuditorsAUDIT-RELATEDISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Authorise the Audit & Risk Committee to Fix Remuneration of AuditorsAUDIT-RELATEDISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Authorise UK Political Donations and ExpenditureOTHER SOCIAL ISSUESISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Authorise Issue of EquityCAPITAL STRUCTUREISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Authorise Issue of Equity without Pre-emptive RightsCAPITAL STRUCTUREISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Authorise Issue of Equity without Pre-emptive Rights in Connection with an Acquisition or Other Capital InvestmentCAPITAL STRUCTUREISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Authorise Market Purchase of Ordinary SharesCAPITAL STRUCTUREISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Approve the Exemption from Statement of the Name of the Senior Statutory Auditor in Published Copies of the Auditors' ReportsCORPORATE GOVERNANCEISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Authorise the Company to Call General Meeting with Two Weeks' NoticeSHAREHOLDER RIGHTS AND DEFENSESISSUER5217650FOR521765FOR19 GSK PLCG3910J179GB00BN7SWP6305/06/2026Amend Articles of AssociationCORPORATE GOVERNANCEISSUER5217650FOR521765FOR19 GSK PLC37733W204US37733W204405/06/2026To receive and adopt the 2025 Annual ReportCORPORATE GOVERNANCEISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To approve the Annual report on remunerationSECTION 14A SAY-ON-PAY VOTESISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To approve amendments to the Remuneration policySECTION 14A SAY-ON-PAY VOTESISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To elect Luke Miels as a DirectorDIRECTOR ELECTIONSISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To re-elect Sir Jonathan Symonds as a DirectorDIRECTOR ELECTIONSISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To re-elect Julie Brown as a DirectorDIRECTOR ELECTIONSISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To re-elect Elizabeth McKee Anderson as a DirectorDIRECTOR ELECTIONSISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To re-elect Charles Bancroft as a DirectorDIRECTOR ELECTIONSISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To re-elect Dr Hal Barron as a DirectorDIRECTOR ELECTIONSISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To re-elect Dr Anne Beal as a DirectorDIRECTOR ELECTIONSISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To re-elect Wendy Becker as a DirectorDIRECTOR ELECTIONSISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To re-elect Dr Harry C Dietz as a DirectorDIRECTOR ELECTIONSISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To re-elect Dr Jeannie Lee as a DirectorDIRECTOR ELECTIONSISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To re-elect Dr Gavin Screaton as a DirectorDIRECTOR ELECTIONSISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To re-elect Dr Vishal Sikka as a DirectorDIRECTOR ELECTIONSISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To re-appoint the auditorAUDIT-RELATEDISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To determine the remuneration of the auditorAUDIT-RELATEDCOMPENSATIONISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To authorise the company and its subsidiaries to make donations to political organisations and incur political expenditureOTHER SOCIAL ISSUESISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To authorise the allotment of sharesCAPITAL STRUCTUREISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To disapply pre-emption rights - general power (special resolution)CAPITAL STRUCTUREISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To disapply pre-emption rights - in connection with an acquisition or specified capital investment (special resolution)CAPITAL STRUCTUREISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To authorise the company to purchase its own shares (special resolution)CAPITAL STRUCTUREISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To authorise exemption from statement of name of senior statutory auditor (special resolution)CORPORATE GOVERNANCEISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To authorise reduced notice of a general meeting other than an AGM (special resolution)SHAREHOLDER RIGHTS AND DEFENSESISSUER1125320FOR112532FOR19 GSK PLC37733W204US37733W204405/06/2026To approve amendments to the Articles of Association (special resolution)CORPORATE GOVERNANCEISSUER1125320FOR112532FOR19 GUARDANT HEALTH, INC.40131M109US40131M109906/17/2026Election of Class II Directors Ian ClarkDIRECTOR ELECTIONSISSUER438520WITHHOLD43852AGAINST19 GUARDANT HEALTH, INC.40131M109US40131M109906/17/2026Election of Class II Directors Manuel Hidalgo MedinaDIRECTOR ELECTIONSISSUER438520FOR43852FOR19 GUARDANT HEALTH, INC.40131M109US40131M109906/17/2026Ratification of the appointment of Deloitte & Touche LLP as Guardant Health, Inc.'s independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER438520FOR43852FOR19 GUARDANT HEALTH, INC.40131M109US40131M109906/17/2026Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER438520FOR43852FOR19 GUARDANT HEALTH, INC.40131M109US40131M109906/17/2026Non-binding advisory vote on the frequency of stockholder advisory votes regarding compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4385201 YEAR43852FOR19 HALOZYME THERAPEUTICS, INC.40637H109US40637H109505/05/2026Election of Class I Directors Bernadette ConnaughtonDIRECTOR ELECTIONSISSUER632260FOR63226FOR19 HALOZYME THERAPEUTICS, INC.40637H109US40637H109505/05/2026Election of Class I Directors Matthew L. PosardDIRECTOR ELECTIONSISSUER632260FOR63226FOR19 HALOZYME THERAPEUTICS, INC.40637H109US40637H109505/05/2026To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER632260FOR63226FOR19 HALOZYME THERAPEUTICS, INC.40637H109US40637H109505/05/2026To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER632260FOR63226FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025To consider and vote upon a proposal to approve, by ordinary resolution, and adopt the Business Combination Agreement, dated as of February 28, 2025 (as amended by Amendment No. 1 to the Business Combination Agreement, dated as of June 17, 2025, and as it may be further amended, restated, supplemented, or otherwise modified from time to time, the "Business Combination Agreement"), by and among Helix, Helix II Merger Sub, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Helix ("Merger Sub"), and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics), a Delaware corporation ("BBOT"), and the transactions contemplated by the Business Combination Agreement, pursuant to which the following will occur: (1) the domestication of Helix as a Delaware corporation, in which Helix will de-register from the Register of Companies in the Cayman Islands and transfer by way of continuation out of the Cayman Islands and into the State of Delaware so as to migrate to and domesticate as a Delaware corporation in accordance with the Helix Articles, Section 388 of the Delaware General Corporation Law (the "DGCL") and Part XII of the Companies Act (As Revised) of the Cayman Islands (the "Cayman Companies Act") (the "Domestication"); (2) the merger of Merger Sub with and into BBOT with BBOT surviving the merger as a wholly-owned subsidiary of Helix (the "Merger"), in accordance with the Business Combination Agreement and DGCL; and (3) the other transactions contemplated by the Business Combination Agreement and documents related thereto (such transactions, together with the Domestication and the Merger, the "Business Combination"), all as described in more detail in the accompanying proxy statement/prospectus. In connection with the consummation of the Business Combination (the "Closing" and the date of the Closing, the "Closing Date"), Helix will be renamed BridgeBio Oncology Therapeutics, Inc. ("PubCo"). References herein to PubCo denote Helix following the Business Combination. We refer to this proposal as the "Business Combination Proposal." A copy of the Business Combination Agreement is attached to the accompanying proxy statement/prospectus as Annex A.EXTRAORDINARY TRANSACTIONSISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025The Domestication Proposal - to consider and vote upon a proposal to approve, by special resolution, the deregistration of Helix from the Registrar of Companies in the Cayman Islands (the "Cayman Registrar") and transfer by way of continuation out of the Cayman Islands and into the State of Delaware so as to migrate to and domesticate as a Delaware corporation in accordance with the Helix Articles, Section 388 of the DGCL, and Part XII of the Cayman Companies Act.EXTRAORDINARY TRANSACTIONSISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025The Stock Issuance Proposal - to consider and vote upon a proposal to approve, by ordinary resolution, including for purposes of complying with the applicable provisions of Nasdaq Listing Rules 5635(a), (b) and (d), the issuance or potential issuance of (i) shares of common stock, par value $0.0001 per share, of PubCo (the "PubCo Common Stock") to the shareholders of Helix in the Domestication and stockholders of BBOT in the Merger pursuant to the Business Combination Agreement, (ii) shares of PubCo Common Stock to the PIPE Investors in the PIPE Investment pursuant to the Subscription Agreements, and (iii) any other issuances of PubCo Common Stock and securities convertible into or exercisable for PubCo Common Stock pursuant to subscription, purchase or similar agreements Helix has entered, or may enter, into prior to Closing.CAPITAL STRUCTUREISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025The Organizational Documents Proposal - to consider and vote upon a proposal to approve, by special resolution, the proposed new certificate of incorporation of PubCo (the "PubCo Charter") and the proposed new bylaws of PubCo (the "PubCo Bylaws" and, together with the PubCo Charter, the "PubCo Organizational Documents") in connection with the Business Combination. The form of each of the PubCo Charter and the PubCo Bylaws is attached to the proxy statement/prospectus as Annex I and Annex J, respectively.CORPORATE GOVERNANCEISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025Authorized Shares - A proposal to amend the Helix Articles to authorize the change in the authorized capital stock of Helix from (i) 500,000,000 Helix Class A Shares, 50,000,000 Helix Class B Shares and 5,000,000 preference shares, par value $0.0001 per share, to (ii) 500,000,000 shares of PubCo Common Stock and 10,000,000 shares of undesignated PubCo preferred stock.CAPITAL STRUCTUREISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025Exclusive Forum Provision - A proposal to amend the Helix Articles to authorize adopting Delaware as the exclusive forum for certain stockholder litigation.SHAREHOLDER RIGHTS AND DEFENSESISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025Adoption of Supermajority Vote Requirement to Amend the Proposed Organizational Documents - A proposal to amend the Helix Articles to approve provisions requiring the affirmative vote of at least (i) two-thirds of the outstanding shares of capital stock entitled to vote to adopt, amend or repeal the PubCo Bylaws and (ii) a majority of PubCo's then outstanding common stock (except where a lower threshold is provided by the DGCL) for amendments to the PubCo Charter.SHAREHOLDER RIGHTS AND DEFENSESISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025Removal of Directors - A proposal to amend the Helix Articles to approve provisions permitting the removal of a director only for cause and only by the affirmative vote of not less than two-thirds of the outstanding shares entitled to vote at an election of directors, voting together as a single class.SHAREHOLDER RIGHTS AND DEFENSESISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025Action by Written Consent of Stockholders - A proposal to amend the Helix Articles to approve provisions requiring stockholders to take action at an annual or special meeting and prohibiting stockholder action by written consent in lieu of a meeting.SHAREHOLDER RIGHTS AND DEFENSESISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025Other Changes in Connection with Adoption of the proposed PubCo Organizational Documents - A proposal to amend the Helix Articles to authorize (1) changing the corporate name from "Helix Acquisition Corp. II" to "BridgeBio Oncology Therapeutics, Inc.", (2) making PubCo's corporate existence perpetual, and (3) removing certain provisions related to Helix's status as a blank check company that will no longer be applicable upon consummation of the Business Combination.CORPORATE GOVERNANCEISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025The Incentive Plan Proposal - to consider and vote upon a proposal to approve, by ordinary resolution, the BridgeBio Oncology Therapeutics, Inc. 2025 Stock Option and Incentive Plan (the "PubCo Incentive Plan").COMPENSATIONISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025The ESPP Proposal - to consider and vote upon a proposal to approve, by ordinary resolution, the BridgeBio Oncology Therapeutics, Inc. 2025 Employee Stock Purchase Plan (the "ESPP").COMPENSATIONISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025DIRECTOR: Eli Wallace, Ph.DDIRECTOR ELECTIONSISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025DIRECTOR: Neil Kumar, Ph.DDIRECTOR ELECTIONSISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025DIRECTOR: Frank McCormick, Ph.D.DIRECTOR ELECTIONSISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025DIRECTOR: Praveen Tipirneni, M.D.DIRECTOR ELECTIONSISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025DIRECTOR: Michelle DoigDIRECTOR ELECTIONSISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025DIRECTOR: Bihua ChenDIRECTOR ELECTIONSISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025DIRECTOR: Raymond Kelleher, M.D.DIRECTOR ELECTIONSISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025DIRECTOR: Jake Bauer, M.B.A.DIRECTOR ELECTIONSISSUER5444650FOR544465FOR19 HELIX ACQUISITION CORP. IIG4444H101KYG4444H101108/04/2025The Adjournment Proposal - to consider and vote upon a proposal to approve, by ordinary resolution, the adjournment of the EGM to a later date or dates, if necessary or desirable.CORPORATE GOVERNANCEISSUER5444650FOR544465FOR19 HOLOGIC, INC.436440101US436440101202/05/2026A proposal to adopt the Agreement and Plan of Merger, dated as of October 21, 2025 (as it may be amended or supplemented from time to time, the "merger agreement"), by and among Hologic, Inc. (the "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, and on the terms and subject to the conditions thereof, Merger Sub will be merged with and into the Company (the "merger"), with the Company surviving the merger as a wholly owned subsidiary of Parent.EXTRAORDINARY TRANSACTIONSISSUER1391180FOR139118FOR19 HOLOGIC, INC.436440101US436440101202/05/2026A proposal to approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to the named executive officers of the Company in connection with the transactions contemplated by the merger agreement, including consummation of the merger.SECTION 14A SAY-ON-PAY VOTESISSUER1391180FOR139118FOR19 HOLOGIC, INC.436440101US436440101202/05/2026A proposal to approve any adjournment of the special meeting for the purpose of soliciting additional proxies if there are insufficient votes at the special meeting to adopt the merger agreement.CORPORATE GOVERNANCEISSUER1391180FOR139118FOR19 ILLUMINA, INC.452327109US452327109005/21/2026Election of Directors Caroline D. DorsaDIRECTOR ELECTIONSISSUER1163380FOR116338FOR19 ILLUMINA, INC.452327109US452327109005/21/2026Election of Directors Scott Gottlieb, M.D.DIRECTOR ELECTIONSISSUER1163380FOR116338FOR19 ILLUMINA, INC.452327109US452327109005/21/2026Election of Directors David P. KingDIRECTOR ELECTIONSISSUER1163380FOR116338FOR19 ILLUMINA, INC.452327109US452327109005/21/2026Election of Directors Keith A. MeisterDIRECTOR ELECTIONSISSUER1163380FOR116338FOR19 ILLUMINA, INC.452327109US452327109005/21/2026Election of Directors Anna RichoDIRECTOR ELECTIONSISSUER1163380FOR116338FOR19 ILLUMINA, INC.452327109US452327109005/21/2026Election of Directors Philip W. SchillerDIRECTOR ELECTIONSISSUER1163380FOR116338FOR19 ILLUMINA, INC.452327109US452327109005/21/2026Election of Directors Susan E. SiegelDIRECTOR ELECTIONSISSUER1163380FOR116338FOR19 ILLUMINA, INC.452327109US452327109005/21/2026Election of Directors Jacob Thaysen, Ph.D.DIRECTOR ELECTIONSISSUER1163380FOR116338FOR19 ILLUMINA, INC.452327109US452327109005/21/2026Election of Directors Scott B. UllemDIRECTOR ELECTIONSISSUER1163380FOR116338FOR19 ILLUMINA, INC.452327109US452327109005/21/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending January 3, 2027.AUDIT-RELATEDISSUER1163380FOR116338FOR19 ILLUMINA, INC.452327109US452327109005/21/2026To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1163380FOR116338FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026Elect Director Siddharth KaulDIRECTOR ELECTIONSISSUER3219000FOR321900FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026Elect Director William PaoDIRECTOR ELECTIONSISSUER3219000FOR321900FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026Elect Director Kristine PetersonDIRECTOR ELECTIONSISSUER3219000FOR321900FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026Advisory Vote to Ratify Named Executive Officers' CompensationSECTION 14A SAY-ON-PAY VOTESISSUER3219000FOR321900FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026Ratify Deloitte LLP as AuditorsAUDIT-RELATEDISSUER3219000FOR321900FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026Reappoint Deloitte LLP as Statutory AuditorsAUDIT-RELATEDISSUER3219000FOR321900FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026Authorize Board to Fix Remuneration of AuditorsAUDIT-RELATEDISSUER3219000FOR321900FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER3219000FOR321900FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026Approve Remuneration ReportSECTION 14A SAY-ON-PAY VOTESISSUER3219000FOR321900FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026Authorize UK Political Donations and ExpenditureOTHER SOCIAL ISSUESISSUER3219000FOR321900FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To re-appoint Siddharth Kaul as a director who retires in accordance with the articles of association. Siddharth KaulDIRECTOR ELECTIONSISSUER372260FOR37226FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To re-appoint William Pao, M.D., Ph.D. as a director who retires in accordance with the articles of association. William Pao, M.D., Ph.D.DIRECTOR ELECTIONSISSUER372260FOR37226FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To re-appoint Kristine Peterson as a director who retires in accordance with the articles of association. Kristine PetersonDIRECTOR ELECTIONSISSUER372260FOR37226FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To approve, on advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER372260FOR37226FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To ratify the appointment of Deloitte LLP, a limited liability partnership organized under the laws of England, as our U.S. independent registered public accounting firm for the year ending 31 December 2026.AUDIT-RELATEDISSUER372260FOR37226FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To re-appoint Deloitte LLP, a limited liability partnership organized under the laws of England, as our U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders.AUDIT-RELATEDISSUER372260FOR37226FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To authorize the audit committee to determine the U.K. statutory auditors' remuneration for the year ending 31 December 2026.AUDIT-RELATEDCOMPENSATIONISSUER372260FOR37226FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To receive and adopt the U.K. statutory annual accounts and reports for the year ended 31 December 2025.CORPORATE GOVERNANCEISSUER372260FOR37226FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To approve our directors' remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the attached proxy statement and on pages 26 to 56 of the 2025 U.K. Annual Report (excluding the directors' remuneration policy set out on 26 to 56 2025 U.K. Annual Report (excluding the directors' remuneration policy set out on A7 to A18 of Annex A).SECTION 14A SAY-ON-PAY VOTESISSUER372260FOR37226FOR19 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To authorize the Company and all of its subsidiaries to make political donations and incur political expenditure.OTHER SOCIAL ISSUESISSUER372260FOR37226FOR19 IMMUNOME INC.45257U108US45257U108806/09/2026To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until the 2029 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal. James BoylanDIRECTOR ELECTIONSISSUER714500FOR71450FOR19 IMMUNOME INC.45257U108US45257U108806/09/2026To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until the 2029 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal. Sandra M. Swain, M.D.DIRECTOR ELECTIONSISSUER714500FOR71450FOR19 IMMUNOME INC.45257U108US45257U108806/09/2026To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until the 2029 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal. Philip WagenheimDIRECTOR ELECTIONSISSUER714500FOR71450FOR19 IMMUNOME INC.45257U108US45257U108806/09/2026To ratify the appointment of Ernst & Young LLP our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER714500FOR71450FOR19 IMMUNOME INC.45257U108US45257U108806/09/2026To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER714500FOR71450FOR19 IMMUNOME INC.45257U108US45257U108806/09/2026To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER7145001 YEAR71450FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Julian C. BakerDIRECTOR ELECTIONSISSUER333897100FOR33389FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Jean-Jacques BienaiméDIRECTOR ELECTIONSISSUER333897100FOR33389FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Otis W. BrawleyDIRECTOR ELECTIONSISSUER333897100FOR33389FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Paul J. ClancyDIRECTOR ELECTIONSISSUER333897100FOR33389FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Jacqualyn A. FouseDIRECTOR ELECTIONSISSUER333897100FOR33389FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Edmund P. HarriganDIRECTOR ELECTIONSISSUER333897100FOR33389FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Katherine A. HighDIRECTOR ELECTIONSISSUER333897100FOR33389FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: William J. MeuryDIRECTOR ELECTIONSISSUER333897100FOR33389FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER333897100FOR33389FOR19 INCYTE CORPORATION45337C102US45337C102706/08/2026Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER333897100FOR33389FOR19 INSULET CORPORATION45784P101US45784P101205/20/2026DIRECTOR: Luciana BorioDIRECTOR ELECTIONSISSUER214930FOR21493FOR19 INSULET CORPORATION45784P101US45784P101205/20/2026DIRECTOR: Michael R. MinogueDIRECTOR ELECTIONSISSUER214930FOR21493FOR19 INSULET CORPORATION45784P101US45784P101205/20/2026DIRECTOR: Timothy C. StonesiferDIRECTOR ELECTIONSISSUER214930FOR21493FOR19 INSULET CORPORATION45784P101US45784P101205/20/2026To approve, on a non-binding, advisory basis, the compensation of certain executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER214930FOR21493FOR19 INSULET CORPORATION45784P101US45784P101205/20/2026To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER214930FOR21493FOR19 INTELLIA THERAPEUTICS, INC.45826J105US45826J105106/09/2026Election of three class I directors to our board of directors, each to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal. Muna Bhanji, R.Ph.DIRECTOR ELECTIONSISSUER1315200FOR131520FOR19 INTELLIA THERAPEUTICS, INC.45826J105US45826J105106/09/2026Election of three class I directors to our board of directors, each to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal. Brian GoffDIRECTOR ELECTIONSISSUER1315200FOR131520FOR19 INTELLIA THERAPEUTICS, INC.45826J105US45826J105106/09/2026Election of three class I directors to our board of directors, each to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal. Jesse Goodman, M.D., M.P.H.DIRECTOR ELECTIONSISSUER1315200FOR131520FOR19 INTELLIA THERAPEUTICS, INC.45826J105US45826J105106/09/2026Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1315200FOR131520FOR19 INTELLIA THERAPEUTICS, INC.45826J105US45826J105106/09/2026Approval, on a non-binding advisory basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1315200FOR131520FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors Craig H. Barratt, Ph.D.DIRECTOR ELECTIONSISSUER235730FOR23573FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors Joseph C. BeeryDIRECTOR ELECTIONSISSUER235730FOR23573FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors Lewis ChewDIRECTOR ELECTIONSISSUER235730FOR23573FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors Gary S. Guthart, Ph.D.DIRECTOR ELECTIONSISSUER235730FOR23573FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors Sreelakshmi KolliDIRECTOR ELECTIONSISSUER235730FOR23573FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors Amy L. Ladd, M.D.DIRECTOR ELECTIONSISSUER235730FOR23573FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors Keith R. Leonard, Jr.DIRECTOR ELECTIONSISSUER235730FOR23573FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors Jami Dover NachtsheimDIRECTOR ELECTIONSISSUER235730FOR23573FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors Monica P. Reed, M.D.DIRECTOR ELECTIONSISSUER235730FOR23573FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026Election of Directors David J. RosaDIRECTOR ELECTIONSISSUER235730FOR23573FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026To approve, by advisory vote, the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER235730FOR23573FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026The ratification of appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER235730FOR23573FOR19 INTUITIVE SURGICAL, INC.46120E602US46120E602304/30/2026To approve the amendment and restatement of the Company's Amended and Restated 2010 Incentive Award Plan.COMPENSATIONISSUER235730FOR23573FOR19 IONIS PHARMACEUTICALS, INC.462222100US462222100406/04/2026Election of Directors Spencer R. BerthelsenDIRECTOR ELECTIONSISSUER701730FOR70173FOR19 IONIS PHARMACEUTICALS, INC.462222100US462222100406/04/2026Election of Directors Joan E. HermanDIRECTOR ELECTIONSISSUER701730FOR70173FOR19 IONIS PHARMACEUTICALS, INC.462222100US462222100406/04/2026To make an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER701730FOR70173FOR19 IONIS PHARMACEUTICALS, INC.462222100US462222100406/04/2026To approve an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares.COMPENSATIONISSUER701730FOR70173FOR19 IONIS PHARMACEUTICALS, INC.462222100US462222100406/04/2026To approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for purchase under such plan by 750,000 shares and remove the termination date of the plan.COMPENSATIONISSUER701730FOR70173FOR19 IONIS PHARMACEUTICALS, INC.462222100US462222100406/04/2026To ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year.AUDIT-RELATEDISSUER701730FOR70173FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i). Ari BousbibDIRECTOR ELECTIONSISSUER467470FOR46747FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i). Carol J. BurtDIRECTOR ELECTIONSISSUER467470FOR46747FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i). John G. DanhaklDIRECTOR ELECTIONSISSUER467470FOR46747FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i). James A. FasanoDIRECTOR ELECTIONSISSUER467470FOR46747FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i). Colleen A. GogginsDIRECTOR ELECTIONSISSUER467470FOR46747FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i). William G. Kaelin Jr., M.D.DIRECTOR ELECTIONSISSUER467470FOR46747FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i). John M. Leonard, M.D.DIRECTOR ELECTIONSISSUER467470FOR46747FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i). Leslie Wims MorrisDIRECTOR ELECTIONSISSUER467470FOR46747FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i). Sheila A. StampsDIRECTOR ELECTIONSISSUER467470FOR46747FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026Approve an advisory (non-binding) resolution to approve IQVIA's executive compensation (say-on-pay).SECTION 14A SAY-ON-PAY VOTESISSUER467470FOR46747FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026Ratification of the appointment of PricewaterhouseCoopers LLP as IQVIA's independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER467470FOR46747FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026Approve the adoption of the IQVIA Holdings Inc. 2026 Incentive and Stock Award Plan.COMPENSATIONISSUER467470FOR46747FOR19 IQVIA HOLDINGS INC.46266C105US46266C105304/23/2026If properly presented, a stockholder proposal concerning separate Chairman and Chief Executive Officer roles.CORPORATE GOVERNANCESECURITY HOLDER467470AGAINST46747FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Mary C. BeckerleDIRECTOR ELECTIONSISSUER905990FOR90599FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Jennifer A. DoudnaDIRECTOR ELECTIONSISSUER905990FOR90599FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Joaquin DuatoDIRECTOR ELECTIONSISSUER905990FOR90599FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Marillyn A. HewsonDIRECTOR ELECTIONSISSUER905990FOR90599FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Paula A. JohnsonDIRECTOR ELECTIONSISSUER905990FOR90599FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Hubert JolyDIRECTOR ELECTIONSISSUER905990FOR90599FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Mark B. McClellanDIRECTOR ELECTIONSISSUER905990FOR90599FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors John G. MorikisDIRECTOR ELECTIONSISSUER905990FOR90599FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Daniel E. PintoDIRECTOR ELECTIONSISSUER905990FOR90599FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Mark A. WeinbergerDIRECTOR ELECTIONSISSUER905990FOR90599FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Nadja Y. WestDIRECTOR ELECTIONSISSUER905990FOR90599FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Election of Directors Eugene A. WoodsDIRECTOR ELECTIONSISSUER905990FOR90599FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Advisory Vote to Approve Named Executive Officer CompensationSECTION 14A SAY-ON-PAY VOTESISSUER905990FOR90599FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Ratification of Appointment of PricewaterhouseCoopers LLP as the Independent Registered Public Accounting FirmAUDIT-RELATEDISSUER905990FOR90599FOR19 JOHNSON & JOHNSON478160104US478160104604/23/2026Independent Board ChairCORPORATE GOVERNANCESECURITY HOLDER905990AGAINST90599FOR19 KINIKSA PHARMACEUTICAL INTERNATIONAL PLCG52694109GB00BRXB0C0705/29/2026Election of Class II Director to serve until the 2029 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Stephen R. BiggarDIRECTOR ELECTIONSISSUER640370FOR64037FOR19 KINIKSA PHARMACEUTICAL INTERNATIONAL PLCG52694109GB00BRXB0C0705/29/2026Election of Class II Director to serve until the 2029 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: G. Bradley ColeDIRECTOR ELECTIONSISSUER640370FOR64037FOR19 KINIKSA PHARMACEUTICAL INTERNATIONAL PLCG52694109GB00BRXB0C0705/29/2026Election of Class II Director to serve until the 2029 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Barry D. QuartDIRECTOR ELECTIONSISSUER640370FOR64037FOR19 KINIKSA PHARMACEUTICAL INTERNATIONAL PLCG52694109GB00BRXB0C0705/29/2026To approve the appointment of PricewaterhouseCoopers LLP ("PwC") as the Company's UK statutory auditors until the close of the 2027 Annual General Meeting of Shareholders.AUDIT-RELATEDISSUER640370FOR64037FOR19 KINIKSA PHARMACEUTICAL INTERNATIONAL PLCG52694109GB00BRXB0C0705/29/2026To ratify the appointment of PwC as the Company's US independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER640370FOR64037FOR19 KINIKSA PHARMACEUTICAL INTERNATIONAL PLCG52694109GB00BRXB0C0705/29/2026To authorize the Company's Board of Directors, through its Audit Committee, to determine PwC's remuneration in its capacity as our UK statutory auditors until the close of the 2027 Annual General Meeting of Shareholders.AUDIT-RELATEDCOMPENSATIONISSUER640370FOR64037FOR19 KINIKSA PHARMACEUTICAL INTERNATIONAL PLCG52694109GB00BRXB0C0705/29/2026To receive the Company's UK statutory annual accounts and report for the period ended December 31, 2025.CORPORATE GOVERNANCEISSUER640370FOR64037FOR19 KINIKSA PHARMACEUTICAL INTERNATIONAL PLCG52694109GB00BRXB0C0705/29/2026To approve, on an advisory (non-binding) basis, the Company's UK Statutory Directors' Annual Remuneration Report for the period ended December 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER640370FOR64037FOR19 KINIKSA PHARMACEUTICAL INTERNATIONAL PLCG52694109GB00BRXB0C0705/29/2026To approve the Company's UK Statutory Directors' Remuneration Policy.SECTION 14A SAY-ON-PAY VOTESISSUER640370FOR64037FOR19 KINIKSA PHARMACEUTICAL INTERNATIONAL PLCG52694109GB00BRXB0C0705/29/2026To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER640370FOR64037FOR19 KODIAK SCIENCES INC.50015M109US50015M109906/02/2026Elect three Class II directors nominated by our board and named in this proxy statement. Charles A. BancroftDIRECTOR ELECTIONSISSUER215420WITHHOLD21542AGAINST19 KODIAK SCIENCES INC.50015M109US50015M109906/02/2026Elect three Class II directors nominated by our board and named in this proxy statement. Bassil I. Dahiyat, Ph.D.DIRECTOR ELECTIONSISSUER215420FOR21542FOR19 KODIAK SCIENCES INC.50015M109US50015M109906/02/2026Elect three Class II directors nominated by our board and named in this proxy statement. Taiyin Yang, Ph.D.DIRECTOR ELECTIONSISSUER215420FOR21542FOR19 KODIAK SCIENCES INC.50015M109US50015M109906/02/2026Approve, on an advisory basis, the compensation of Kodiak's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER215420FOR21542FOR19 KODIAK SCIENCES INC.50015M109US50015M109906/02/2026Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER215420FOR21542FOR19 KYMERA THERAPEUTICS, INC.501575104US501575104406/24/2026DIRECTOR: Bruce Booth, D.Phil.DIRECTOR ELECTIONSISSUER139370FOR13937FOR19 KYMERA THERAPEUTICS, INC.501575104US501575104406/24/2026DIRECTOR: Nello Mainolfi, Ph.D.DIRECTOR ELECTIONSISSUER139370FOR13937FOR19 KYMERA THERAPEUTICS, INC.501575104US501575104406/24/2026DIRECTOR: John Maraganore, Ph.D.DIRECTOR ELECTIONSISSUER139370FOR13937FOR19 KYMERA THERAPEUTICS, INC.501575104US501575104406/24/2026DIRECTOR: Elena Ridloff, CFADIRECTOR ELECTIONSISSUER139370FOR13937FOR19 KYMERA THERAPEUTICS, INC.501575104US501575104406/24/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers; andSECTION 14A SAY-ON-PAY VOTESISSUER139370FOR13937FOR19 KYMERA THERAPEUTICS, INC.501575104US501575104406/24/2026To ratify the appointment of Ernst &Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER139370FOR13937FOR19 LANTHEUS HOLDINGS, INC.516544103US516544103204/30/2026The election of four Class II directors to our Board of Directors. Ms. Minnie Baylor-HenryDIRECTOR ELECTIONSISSUER482940FOR48294FOR19 LANTHEUS HOLDINGS, INC.516544103US516544103204/30/2026The election of four Class II directors to our Board of Directors. Mr. Heinz MäusliDIRECTOR ELECTIONSISSUER482940FOR48294FOR19 LANTHEUS HOLDINGS, INC.516544103US516544103204/30/2026The election of four Class II directors to our Board of Directors. Ms. Julie McHughDIRECTOR ELECTIONSISSUER482940FOR48294FOR19 LANTHEUS HOLDINGS, INC.516544103US516544103204/30/2026The election of four Class II directors to our Board of Directors. Dr. Phuong Khanh (P.K.) MorrowDIRECTOR ELECTIONSISSUER482940FOR48294FOR19 LANTHEUS HOLDINGS, INC.516544103US516544103204/30/2026The approval, on an advisory basis, of the compensation paid to our named executive officers (commonly referred to as ''say on pay'').SECTION 14A SAY-ON-PAY VOTESISSUER482940FOR48294FOR19 LANTHEUS HOLDINGS, INC.516544103US516544103204/30/2026The approval, on an advisory basis, of the frequency of holding future ''say on pay'' votes.SECTION 14A SAY-ON-PAY VOTESISSUER4829401 YEAR48294FOR19 LANTHEUS HOLDINGS, INC.516544103US516544103204/30/2026The approval of an amendment to our Amended and Restated Certificate of Incorporation to declassify our Board of Directors.SHAREHOLDER RIGHTS AND DEFENSESISSUER482940FOR48294FOR19 LANTHEUS HOLDINGS, INC.516544103US516544103204/30/2026The approval of the Lantheus Holdings, Inc. Amended and Restated 2026 Equity Incentive Plan.COMPENSATIONISSUER482940FOR48294FOR19 LANTHEUS HOLDINGS, INC.516544103US516544103204/30/2026The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER482940FOR48294FOR19 LB PHARMACEUTICALS INC.50180M108US50180M108006/03/2026DIRECTOR: Robert A. Lenz MD., PhDDIRECTOR ELECTIONSISSUER12488783100FOR124887FOR19 LB PHARMACEUTICALS INC.50180M108US50180M108006/03/2026DIRECTOR: Rebecca LuseDIRECTOR ELECTIONSISSUER12488783100FOR124887FOR19 LB PHARMACEUTICALS INC.50180M108US50180M108006/03/2026DIRECTOR: Ran NussbaumDIRECTOR ELECTIONSISSUER12488783100FOR124887FOR19 LB PHARMACEUTICALS INC.50180M108US50180M108006/03/2026To ratify the appointment by the Audit Committee of the Board of Directors of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER12488783100FOR124887FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Approve Non-Financial ReportOTHER SOCIAL ISSUESISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Approve Remuneration Report (Non-Binding)SECTION 14A SAY-ON-PAY VOTESISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Approve Discharge of Board and Senior ManagementDIRECTOR ELECTIONSISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Approve Allocation of Income and Dividends of CHF 5.00 per ShareCAPITAL STRUCTUREISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Reelect Jean-Marc Huet as Director and Board ChairDIRECTOR ELECTIONSISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Reelect Juan Andres as DirectorDIRECTOR ELECTIONSISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Reelect Eric Drape as DirectorDIRECTOR ELECTIONSISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Reelect Marion Helmes as DirectorDIRECTOR ELECTIONSISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Reelect Angelica Kohlmann as DirectorDIRECTOR ELECTIONSISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Reelect Christoph Maeder as DirectorDIRECTOR ELECTIONSISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Reelect David Meline as DirectorDIRECTOR ELECTIONSISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Elect Sami Atiya as DirectorDIRECTOR ELECTIONSISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Elect Stephen Fry as DirectorDIRECTOR ELECTIONSISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Elect Claudia Suessmuth-Dyckerhoff as DirectorDIRECTOR ELECTIONSISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Reappoint Eric Drape as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Reappoint Angelica Kohlmann as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Reappoint Christoph Maeder as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Reappoint David Meline as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Appoint Claudia Suessmuth-Dyckerhoff as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Ratify Deloitte AG as Auditors for Fiscal Year 2027AUDIT-RELATEDISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Designate Lenz Caemmerer as Independent ProxyCORPORATE GOVERNANCEISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Approve Remuneration of Directors in the Amount of CHF 4.3 MillionCOMPENSATIONISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Approve Variable Short-Term Remuneration of Executive Committee in the Amount of CHF 5.9 MillionCOMPENSATIONISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Approve Fixed and Variable Long-Term Remuneration of Executive Committee in the Amount of CHF 26.1 MillionCOMPENSATIONISSUER232580FOR23258FOR19 LONZA GROUP AGH50524133CH001384101705/08/2026Transact Other Business (Voting)CORPORATE GOVERNANCEISSUER232580ABSTAIN23258AGAINST19 LONZA GROUP AGH50524133CH001384101705/08/2026Share Re-registration ConsentCORPORATE GOVERNANCEISSUER232580FOR23258FOR19 MAPLIGHT THERAPEUTICS, INC.56565P103US56565P103006/23/2026To elect the three Class I Director nominees named in the Proxy Statement to serve until the 2029 annual meeting of our stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal. Martin BablerDIRECTOR ELECTIONSISSUER211120FOR21112FOR19 MAPLIGHT THERAPEUTICS, INC.56565P103US56565P103006/23/2026To elect the three Class I Director nominees named in the Proxy Statement to serve until the 2029 annual meeting of our stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal. Troy CoxDIRECTOR ELECTIONSISSUER211120FOR21112FOR19 MAPLIGHT THERAPEUTICS, INC.56565P103US56565P103006/23/2026To elect the three Class I Director nominees named in the Proxy Statement to serve until the 2029 annual meeting of our stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal. George PavlovDIRECTOR ELECTIONSISSUER211120FOR21112FOR19 MAPLIGHT THERAPEUTICS, INC.56565P103US56565P103006/23/2026To ratify the appointment by the Audit Committee of our Board of Directors of RSM US LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER211120FOR21112FOR19 MAZE THERAPEUTICS INC578784100US578784100706/08/2026DIRECTOR: Jason Coloma, Ph.D.DIRECTOR ELECTIONSISSUER447250FOR44725FOR19 MAZE THERAPEUTICS INC578784100US578784100706/08/2026DIRECTOR: Neil Kumar, Ph.D.DIRECTOR ELECTIONSISSUER447250FOR44725FOR19 MAZE THERAPEUTICS INC578784100US578784100706/08/2026Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER447250FOR44725FOR19 MBX BIOSCIENCES55287L101US55287L101706/04/2026Election of two Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholder and until such person's successor is duly elected and qualified, or until their earlier death, resignation or removal: Patrick J. HeronDIRECTOR ELECTIONSISSUER1285490FOR128549FOR19 MBX BIOSCIENCES55287L101US55287L101706/04/2026Election of two Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholder and until such person's successor is duly elected and qualified, or until their earlier death, resignation or removal: Edward T. MathersDIRECTOR ELECTIONSISSUER1285490WITHHOLD128549AGAINST19 MBX BIOSCIENCES55287L101US55287L101706/04/2026Ratification of the appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026.AUDIT-RELATEDISSUER1285490FOR128549FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Dominic J. CarusoDIRECTOR ELECTIONSISSUER130760FOR13076FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Lynne M. DoughtieDIRECTOR ELECTIONSISSUER130760FOR13076FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: W. Roy DunbarDIRECTOR ELECTIONSISSUER130760FOR13076FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Deborah Dunsire, M.D.DIRECTOR ELECTIONSISSUER130760FOR13076FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Julie L. Gerberding, M.D., M.P.H.DIRECTOR ELECTIONSISSUER130760FOR13076FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: James H. HintonDIRECTOR ELECTIONSISSUER130760FOR13076FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Donald R. KnaussDIRECTOR ELECTIONSISSUER130760FOR13076FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Bradley E. LermanDIRECTOR ELECTIONSISSUER130760FOR13076FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Maria N. MartinezDIRECTOR ELECTIONSISSUER130760FOR13076FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Kevin M. OzanDIRECTOR ELECTIONSISSUER130760FOR13076FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Brian S. TylerDIRECTOR ELECTIONSISSUER130760FOR13076FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Election of Director for a One-Year Term: Kathleen Wilson-ThompsonDIRECTOR ELECTIONSISSUER130760FOR13076FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Ratification of Appointment of Deloitte & Touche LLP as the Company's Independent Registered Public Accounting Firm for Fiscal Year 2026AUDIT-RELATEDISSUER130760FOR13076FOR19 MCKESSON CORPORATION58155Q103US58155Q103107/30/2025Advisory Vote to Approve the Company's Executive CompensationSECTION 14A SAY-ON-PAY VOTESISSUER130760FOR13076FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Charles N. MillsDIRECTOR ELECTIONSISSUER1418630FOR141863FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Joseph P. BarattaDIRECTOR ELECTIONSISSUER1418630FOR141863FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Jacob D. BestDIRECTOR ELECTIONSISSUER1418630FOR141863FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Todd M. BluedornDIRECTOR ELECTIONSISSUER1418630FOR141863FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: James M. BoyleDIRECTOR ELECTIONSISSUER1418630FOR141863FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Richard A. GalantiDIRECTOR ELECTIONSISSUER1418630FOR141863FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Patrick J. HealyDIRECTOR ELECTIONSISSUER1418630FOR141863FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Andrew J. MillsDIRECTOR ELECTIONSISSUER1418630FOR141863FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Robert R. SchmidtDIRECTOR ELECTIONSISSUER1418630FOR141863FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Anushka M. SunderDIRECTOR ELECTIONSISSUER1418630FOR141863FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Thomas W. SweetDIRECTOR ELECTIONSISSUER1418630FOR141863FOR19 MEDLINE INC.58507V107US58507V107006/11/2026DIRECTOR: Stephen H. WiseDIRECTOR ELECTIONSISSUER1418630FOR141863FOR19 MEDLINE INC.58507V107US58507V107006/11/2026Advisory Vote to Approve Our Executive Compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1418630FOR141863FOR19 MEDLINE INC.58507V107US58507V107006/11/2026Advisory Vote on the Frequency of Votes on Our Executive Compensation.SECTION 14A SAY-ON-PAY VOTESISSUER14186301 YEAR141863FOR19 MEDLINE INC.58507V107US58507V107006/11/2026Ratification of the Selection of Ernst & Young LLP as Our Independent Auditor for Fiscal Year 2026.AUDIT-RELATEDISSUER1418630FOR141863FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Craig ArnoldDIRECTOR ELECTIONSISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Scott C. DonnellyDIRECTOR ELECTIONSISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Lidia L. FonsecaDIRECTOR ELECTIONSISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); John P. GroetelaarsDIRECTOR ELECTIONSISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Randall J. Hogan, IIIDIRECTOR ELECTIONSISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); William R. JellisonDIRECTOR ELECTIONSISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Joon S. Lee, M.D.DIRECTOR ELECTIONSISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Gregory P. LewisDIRECTOR ELECTIONSISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Kevin E. LoftonDIRECTOR ELECTIONSISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Geoffrey S. MarthaDIRECTOR ELECTIONSISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Elizabeth G. Nabel, M.D.DIRECTOR ELECTIONSISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2026 Annual General Meeting of Medtronic plc (the ''Company''); Kendall J. PowellDIRECTOR ELECTIONSISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Ratifying, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company's independent auditor for fiscal year 2026 and authorizing, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditor's remuneration;AUDIT-RELATEDCOMPENSATIONISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Approving, on an advisory basis, the Company's executive compensation;SECTION 14A SAY-ON-PAY VOTESISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Renewing the Board of Directors' authority to issue shares under Irish law;CAPITAL STRUCTUREISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Renewing the Board of Directors' authority to opt out of pre-emption rights under Irish law;CAPITAL STRUCTUREISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Authorizing the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares;CAPITAL STRUCTUREISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Approving an amendment to Article 177 of the Company's Articles of Association, to facilitate the capitalization of certain of the Company's non-distributable reserves;CAPITAL STRUCTUREISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Approving a Capital Reduction to Create Distributable Reserves under Irish Law; andCAPITAL STRUCTUREISSUER1653940FOR165394FOR19 MEDTRONIC PLCG5960L103IE00BTN1Y11510/16/2025Approving amendments to the Company's Articles of Association, to update the advance notice provisions.SHAREHOLDER RIGHTS AND DEFENSESISSUER1653940FOR165394FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Douglas M. Baker, Jr.DIRECTOR ELECTIONSISSUER2245700FOR224570FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Mary Ellen CoeDIRECTOR ELECTIONSISSUER2245700FOR224570FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Pamela J. CraigDIRECTOR ELECTIONSISSUER2245700FOR224570FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Robert M. DavisDIRECTOR ELECTIONSISSUER2245700FOR224570FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Thomas H. GlocerDIRECTOR ELECTIONSISSUER2245700FOR224570FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Surendralal L. KarsanbhaiDIRECTOR ELECTIONSISSUER2245700FOR224570FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Risa J. Lavizzo-Mourey, M.D.DIRECTOR ELECTIONSISSUER2245700FOR224570FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Stephen L. Mayo, Ph.D.DIRECTOR ELECTIONSISSUER2245700FOR224570FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Paul B. Rothman, M.D.DIRECTOR ELECTIONSISSUER2245700FOR224570FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Patricia F. RussoDIRECTOR ELECTIONSISSUER2245700FOR224570FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Christine E. Seidman, M.D.DIRECTOR ELECTIONSISSUER2245700FOR224570FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Inge G. ThulinDIRECTOR ELECTIONSISSUER2245700FOR224570FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Election of Directors Kathy J. WardenDIRECTOR ELECTIONSISSUER2245700FOR224570FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Non-binding advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2245700FOR224570FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Ratification of the appointment of the Company's independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER2245700FOR224570FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Shareholder proposal regarding a report on DEI risks in federal contracting.CORPORATE GOVERNANCEHUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCESECURITY HOLDER2245700AGAINST224570FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Shareholder proposal regarding a report on healthcare coverage gaps.CORPORATE GOVERNANCEHUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCESECURITY HOLDER2245700AGAINST224570FOR19 MERCK & CO., INC.58933Y105US58933Y105505/26/2026Shareholder proposal regarding a report on political contributions.OTHER SOCIAL ISSUESSECURITY HOLDER2245700AGAINST224570FOR19 MERUS N.V.N5749R100NL001160626412/09/2025Back-End Transactions - (1) To enter into a statutory merger under Dutch law pursuant to which Merus, as disappearing company, will merge with and into New Topco, as surviving company, and (2) to approve, within the meaning of Section 2:107a of the Dutch Civil Code and to the extent required by applicable law, such statutory merger and the subsequent cancellation of all class A shares in the capital of New Topco with repayment and distribution by New Topco of an amount per class A share so cancelled equal to the Offer Consideration, without interest and subject to any applicable withholding taxesEXTRAORDINARY TRANSACTIONSISSUER211870FOR21187FOR19 MERUS N.V.N5749R100NL001160626412/09/2025Back-End Transactions - (1) to amend Menus' Articles of Association to increase Merus' authorized share capital in one or more tranches, and (2) to convert Merus N.V. into a private company with limited liability, promptly following the delisting of Merus' common shares from the Nasdaq Global Market and to amend Menus' Articles of Association accordinglyCORPORATE GOVERNANCEISSUER211870FOR21187FOR19 MERUS N.V.N5749R100NL001160626412/09/2025Effective upon the acceptance for payment by Purchaser for all Common Shares validly tendered and not properly withdrawn pursuant to the Offer prior to the Expiration Time, to provide full and final discharge to each member of the Merus Board for their acts of management or supervision, as applicable, up to and including the date of the EGM to the fullest extent permitted under applicable lawDIRECTOR ELECTIONSISSUER211870FOR21187FOR19 MERUS N.V.N5749R100NL001160626412/09/2025Appointment of Greg Mueller as non-executive director of Merus - Opportunity for Merus Shareholders to make recommendations at the EGM to Merus' non-executive directors in respect of their nomination to appoint a non- executive directorCORPORATE GOVERNANCEISSUER211870FOR21187NONE19 MERUS N.V.N5749R100NL001160626412/09/2025Appointment of Greg Mueller as non-executive director of Merus - Appointment of Greg Mueller as non-executive director of Merus Greg MuellerDIRECTOR ELECTIONSISSUER211870FOR21187FOR19 MERUS N.V.N5749R100NL001160626412/09/2025Appointment of Anthony Pagano as non-executive director of Merus - Opportunity for Merus Shareholders to make recommendations at the EGM to Merus' non-executive directors in respect of their nomination to appoint a non- executive directorCORPORATE GOVERNANCEISSUER211870FOR21187NONE19 MERUS N.V.N5749R100NL001160626412/09/2025Appointment of Anthony Pagano as non-executive director of Merus - Appointment of Anthony Pagano as non-executive director of Merus Anthony PaganoDIRECTOR ELECTIONSISSUER211870FOR21187FOR19 MERUS N.V.N5749R100NL001160626412/09/2025Appointment of Martine van Vugt, Ph.D., as non-executive director of Merus - Opportunity for Merus Shareholders to make recommendations at the EGM to Merus' non-executive directors in respect of their nomination to appoint a non- executive directorCORPORATE GOVERNANCEISSUER211870FOR21187NONE19 MERUS N.V.N5749R100NL001160626412/09/2025Appointment of Martine van Vugt, Ph.D., as non-executive director of Merus - Appointment of Martine van Vugt, Ph.D., as non-executive director of Merus Martine van Vugt, Ph.D.DIRECTOR ELECTIONSISSUER211870FOR21187FOR19 MERUS N.V.N5749R100NL001160626412/09/2025Non-binding advisory proposal to approve certain compensation arrangementsSECTION 14A SAY-ON-PAY VOTESISSUER211870FOR21187FOR19 MODERNA, INC.60770K107US60770K107911/12/2025To approve a one-time stock option exchange program for non-Executive Committee employees of Moderna, Inc. (the "Option Exchange Proposal").COMPENSATIONISSUER453750FOR45375FOR19 MODERNA, INC.60770K107US60770K107911/12/2025To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Option Exchange Proposal (the "Adjournment Proposal").CORPORATE GOVERNANCEISSUER453750FOR45375FOR19 MODERNA, INC.60770K107US60770K107905/06/2026To elect two Class II director nominees set forth in the proxy statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified or such director's earlier death, resignation or removal. Sandra Horning, M.D.DIRECTOR ELECTIONSISSUER4521690AGAINST452169AGAINST19 MODERNA, INC.60770K107US60770K107905/06/2026To elect two Class II director nominees set forth in the proxy statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified or such director's earlier death, resignation or removal. Abbas HussainDIRECTOR ELECTIONSISSUER4521690FOR452169FOR19 MODERNA, INC.60770K107US60770K107905/06/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4521690AGAINST452169AGAINST19 MODERNA, INC.60770K107US60770K107905/06/2026To approve, on a non-binding, advisory basis, the frequency of future non-binding advisory votes to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER45216901 YEAR452169FOR19 MODERNA, INC.60770K107US60770K107905/06/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER4521690FOR452169FOR19 MONTE ROSA THERAPEUTICS, INC.61225M102US61225M102706/11/2026To elect three Class II director nominees to our board of directors, to serve until the Company's 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal; Andrew Schiff, M.D.DIRECTOR ELECTIONSISSUER704060FOR70406FOR19 MONTE ROSA THERAPEUTICS, INC.61225M102US61225M102706/11/2026To elect three Class II director nominees to our board of directors, to serve until the Company's 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal; Chandra P. Leo, M.D.DIRECTOR ELECTIONSISSUER704060FOR70406FOR19 MONTE ROSA THERAPEUTICS, INC.61225M102US61225M102706/11/2026To elect three Class II director nominees to our board of directors, to serve until the Company's 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal; Anthony Manning, Ph.D.DIRECTOR ELECTIONSISSUER704060FOR70406FOR19 MONTE ROSA THERAPEUTICS, INC.61225M102US61225M102706/11/2026To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER704060FOR70406FOR19 MOONLAKE IMMUNOTHERAPEUTICS61559X104KY61559X104506/04/2026Election of the Class I director nominee to serve until the 2029 Annual General Meeting of Shareholders and until his successor is duly elected and qualified. Spike LoyDIRECTOR ELECTIONSISSUER433950FOR43395FOR19 MOONLAKE IMMUNOTHERAPEUTICS61559X104KY61559X104506/04/2026Ratification, by ordinary resolution, of the selection of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER433950FOR43395FOR19 MOONLAKE IMMUNOTHERAPEUTICS61559X104KY61559X104506/04/2026Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER433950FOR43395FOR19 MOONLAKE IMMUNOTHERAPEUTICS61559X104KY61559X104506/04/2026Approval of an amendment and restatement of the Company's 2022 Equity Incentive Plan.COMPENSATIONISSUER433950FOR43395FOR19 NATERA, INC.632307104US632307104206/11/2026DIRECTOR: Rowan Chapman*DIRECTOR ELECTIONSISSUER521220FOR52122FOR19 NATERA, INC.632307104US632307104206/11/2026DIRECTOR: Herm Rosenman*DIRECTOR ELECTIONSISSUER521220FOR52122FOR19 NATERA, INC.632307104US632307104206/11/2026DIRECTOR: Jonathan Sheena*DIRECTOR ELECTIONSISSUER521220FOR52122FOR19 NATERA, INC.632307104US632307104206/11/2026DIRECTOR: Eric H. Rubin#DIRECTOR ELECTIONSISSUER521220FOR52122FOR19 NATERA, INC.632307104US632307104206/11/2026To ratify the appointment of Ernst & Young LLP as Natera, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER521220FOR52122FOR19 NATERA, INC.632307104US632307104206/11/2026To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER521220FOR52122FOR19 NATERA, INC.632307104US632307104206/11/2026To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER5212201 YEAR52122FOR19 NATERA, INC.632307104US632307104206/11/2026To approve an amendment to Natera's 2015 Equity Incentive Plan, as amended and restated.COMPENSATIONISSUER521220FOR52122FOR19 NEUROCRINE BIOSCIENCES, INC.64125C109US64125C109905/27/2026DIRECTOR: Kevin C. Gorman, Ph.D.DIRECTOR ELECTIONSISSUER796760FOR79676FOR19 NEUROCRINE BIOSCIENCES, INC.64125C109US64125C109905/27/2026DIRECTOR: Gary A. LyonsDIRECTOR ELECTIONSISSUER796760FOR79676FOR19 NEUROCRINE BIOSCIENCES, INC.64125C109US64125C109905/27/2026DIRECTOR: Johanna MercierDIRECTOR ELECTIONSISSUER796760FOR79676FOR19 NEUROCRINE BIOSCIENCES, INC.64125C109US64125C109905/27/2026Advisory vote on the compensation paid to the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER796760FOR79676FOR19 NEUROCRINE BIOSCIENCES, INC.64125C109US64125C109905/27/2026To approve an amendment of the Company's 2025 Equity Incentive Plan to increase the aggregate number of shares of common stock reserved for issuance thereunder by 4,000,000 shares; andCOMPENSATIONISSUER796760FOR79676FOR19 NEUROCRINE BIOSCIENCES, INC.64125C109US64125C109905/27/2026To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER796760FOR79676FOR19 NEUROGENE INC.64135M105US64135M105306/03/2026DIRECTOR: Robert Baffi, Ph.D.DIRECTOR ELECTIONSISSUER361990FOR36199FOR19 NEUROGENE INC.64135M105US64135M105306/03/2026DIRECTOR: Rohan PalekarDIRECTOR ELECTIONSISSUER361990FOR36199FOR19 NEUROGENE INC.64135M105US64135M105306/03/2026To approve on an advisory (non-binding) basis the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER361990FOR36199FOR19 NEUROGENE INC.64135M105US64135M105306/03/2026To ratify on an advisory (non-binding) basis the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER361990FOR36199FOR19 NEUROGENE INC.64135M105US64135M105306/03/2026To hold a non-binding advisory vote on whether future non-binding advisory votes on the executive compensation paid by the company to its named executive officers should be held every one, two, or three years.SECTION 14A SAY-ON-PAY VOTESISSUER3619901 YEAR36199FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Share Re-registration ConsentCORPORATE GOVERNANCEISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Approve Non-Financial ReportOTHER SOCIAL ISSUESISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Approve Discharge of Board and Senior ManagementDIRECTOR ELECTIONSISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Approve Allocation of Income and Dividends of CHF 3.70 per ShareCAPITAL STRUCTUREISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Approve CHF 38 Million Reduction in Share Capital via Cancellation of Repurchased SharesCAPITAL STRUCTUREISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Approve Remuneration of Directors in the Amount of CHF 8.2 MillionCOMPENSATIONISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Approve Remuneration of Executive Committee in the Amount of CHF 95 MillionCOMPENSATIONISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Approve Remuneration ReportSECTION 14A SAY-ON-PAY VOTESISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Reelect Giovanni Caforio as Director and Board ChairDIRECTOR ELECTIONSISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Reelect Nancy Andrews as DirectorDIRECTOR ELECTIONSISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Reelect Ton Buechner as DirectorDIRECTOR ELECTIONSISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Reelect Patrice Bula as DirectorDIRECTOR ELECTIONSISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Reelect Elizabeth Doherty as DirectorDIRECTOR ELECTIONSISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Reelect Bridgette Heller as DirectorDIRECTOR ELECTIONSISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Reelect Frans van Houten as DirectorDIRECTOR ELECTIONSISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Reelect Elizabeth McNally as DirectorDIRECTOR ELECTIONSISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Reelect Simon Moroney as DirectorDIRECTOR ELECTIONSISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Reelect Ana de Pro Gonzalo as DirectorDIRECTOR ELECTIONSISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Reelect John Young as DirectorDIRECTOR ELECTIONSISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Elect Charles Swanton as DirectorDIRECTOR ELECTIONSISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Reappoint Patrice Bula as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Reappoint Bridgette Heller as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Reappoint Simon Moroney as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Reappoint John Young as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Appoint Elizabeth McNally as Member of the Compensation CommitteeCORPORATE GOVERNANCEISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Ratify KPMG AG as AuditorsAUDIT-RELATEDISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Designate Peter Zahn as Independent ProxyCORPORATE GOVERNANCEISSUER1043970FOR104397FOR19 NOVARTIS AGH5820Q150CH001200526703/06/2026Transact Other Business (Voting)CORPORATE GOVERNANCEISSUER1043970ABSTAIN104397AGAINST19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors Asaf DanzigerDIRECTOR ELECTIONSISSUER2100160FOR210016FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors William DoyleDIRECTOR ELECTIONSISSUER2100160FOR210016FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors Jeryl HillemanDIRECTOR ELECTIONSISSUER2100160FOR210016FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors David HungDIRECTOR ELECTIONSISSUER2100160FOR210016FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors Frank LeonardDIRECTOR ELECTIONSISSUER2100160FOR210016FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors Kinyip Gabriel LeungDIRECTOR ELECTIONSISSUER2100160FOR210016FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors Martin MaddenDIRECTOR ELECTIONSISSUER2100160FOR210016FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors Allyson OceanDIRECTOR ELECTIONSISSUER2100160FOR210016FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors Timothy ScannellDIRECTOR ELECTIONSISSUER2100160FOR210016FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors Kristin StaffordDIRECTOR ELECTIONSISSUER2100160FOR210016FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026Election of Directors William VernonDIRECTOR ELECTIONSISSUER2100160FOR210016FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026The approval and ratification of the appointment, by the Audit Committee of our Board of Directors, of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the auditor and independent registered public accounting firm of the Company for the Company's fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER2100160FOR210016FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026A non-binding advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER2100160FOR210016FOR19 NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026The approval of our amended and restated 2024 Omnibus Incentive Plan.COMPENSATIONISSUER2100160AGAINST210016AGAINST19 NUVALENT, INC.670703107US670703107506/16/2026Election of the following nominees as Class II directors: Michael L. Meyers, M.D., Ph.D.DIRECTOR ELECTIONSISSUER520240FOR52024FOR19 NUVALENT, INC.670703107US670703107506/16/2026Election of the following nominees as Class II directors: Ron SquarerDIRECTOR ELECTIONSISSUER520240FOR52024FOR19 NUVALENT, INC.670703107US670703107506/16/2026To approve, on an advisory basis, the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER520240FOR52024FOR19 NUVALENT, INC.670703107US670703107506/16/2026To ratify the appointment of KPMG LLP as Nuvalent, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER520240FOR52024FOR19 NUVATION BIO INC.67080N101US67080N101905/21/2026DIRECTOR: Robert BazemoreDIRECTOR ELECTIONSISSUER2838330FOR283833FOR19 NUVATION BIO INC.67080N101US67080N101905/21/2026DIRECTOR: Robert Mashal, M.D.DIRECTOR ELECTIONSISSUER2838330FOR283833FOR19 NUVATION BIO INC.67080N101US67080N101905/21/2026Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER2838330FOR283833FOR19 NUVATION BIO INC.67080N101US67080N101905/21/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER2838330FOR283833FOR19 OCULAR THERAPEUTIX, INC.67576A100US67576A100706/10/2026DIRECTOR: Pravin U. Dugel, M.D.DIRECTOR ELECTIONSISSUER769130FOR76913FOR19 OCULAR THERAPEUTIX, INC.67576A100US67576A100706/10/2026DIRECTOR: Merilee RainesDIRECTOR ELECTIONSISSUER769130FOR76913FOR19 OCULAR THERAPEUTIX, INC.67576A100US67576A100706/10/2026To approve an advisory vote on named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER769130AGAINST76913AGAINST19 OCULAR THERAPEUTIX, INC.67576A100US67576A100706/10/2026To approve, on a non-binding, advisory basis, the frequency of future advisory votes to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER7691301 YEAR76913FOR19 OCULAR THERAPEUTIX, INC.67576A100US67576A100706/10/2026To approve an amendment to the Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as amended, to increase the number of shares of common stock issuable thereunder by 10,000,000 shares.COMPENSATIONISSUER769130FOR76913FOR19 OCULAR THERAPEUTIX, INC.67576A100US67576A100706/10/2026To ratify the appointment of PricewaterhouseCoopers LLP as Ocular Therapeutix's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER769130FOR76913FOR19 ORIC PHARMACEUTICALS, INC.68622P109US68622P109306/18/2026To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal. Jacob M. Chacko, M.DDIRECTOR ELECTIONSISSUER990050FOR99005FOR19 ORIC PHARMACEUTICALS, INC.68622P109US68622P109306/18/2026To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal. Mardi C. DierDIRECTOR ELECTIONSISSUER990050FOR99005FOR19 ORIC PHARMACEUTICALS, INC.68622P109US68622P109306/18/2026To ratify the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER990050FOR99005FOR19 ORIC PHARMACEUTICALS, INC.68622P109US68622P109306/18/2026To approve the ORIC Pharmaceuticals, Inc. 2020 Equity Incentive Plan, as amended and restated.COMPENSATIONISSUER990050AGAINST99005AGAINST19 ORIC PHARMACEUTICALS, INC.68622P109US68622P109306/18/2026To approve, on an advisory basis, executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER990050FOR99005FOR19 ORIC PHARMACEUTICALS, INC.68622P109US68622P109306/18/2026To approve, on an advisory basis, the frequency of future advisory votes on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER9900501 YEAR99005FOR19 ORUKA THERAPEUTICS, INC.687604108US687604108706/02/2026DIRECTOR: Lawrence KleinDIRECTOR ELECTIONSISSUER484260FOR48426FOR19 ORUKA THERAPEUTICS, INC.687604108US687604108706/02/2026DIRECTOR: Chris MartinDIRECTOR ELECTIONSISSUER484260FOR48426FOR19 ORUKA THERAPEUTICS, INC.687604108US687604108706/02/2026To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Oruka Therapeutics, Inc. for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER484260FOR48426FOR19 ORUKA THERAPEUTICS, INC.687604108US687604108706/02/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER484260FOR48426FOR19 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Election of three director nominees to serve as Class III directors whose term will expire in 2029. George M. JenkinsDIRECTOR ELECTIONSISSUER212460FOR21246FOR19 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Election of three director nominees to serve as Class III directors whose term will expire in 2029. Todd C. DavisDIRECTOR ELECTIONSISSUER212460FOR21246FOR19 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Election of three director nominees to serve as Class III directors whose term will expire in 2029. John Doux, M.D.DIRECTOR ELECTIONSISSUER212460FOR21246FOR19 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Ratification of the appointment of Ernst & Young as the Company's independent registered public accounting firm for the 2026 fiscal year.AUDIT-RELATEDISSUER212460FOR21246FOR19 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Approval, on an advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER212460FOR21246FOR19 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Approval, on an advisory basis, of the preferred frequency of future advisory votes on the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2124601 YEAR21246FOR19 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Approval of an amendment to the 2024 Equity Incentive Plan to increase the authorized shares issuable under the 2024 Plan by 750,000 shares.COMPENSATIONISSUER212460FOR21246FOR19 PALVELLA THERAPEUTICS, INC697947109US697947109006/10/2026Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 5.CORPORATE GOVERNANCEISSUER212460FOR21246FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Ronald E. BlaylockDIRECTOR ELECTIONSISSUER1660190FOR166019FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Albert BourlaDIRECTOR ELECTIONSISSUER1660190FOR166019FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Mortimer J. BuckleyDIRECTOR ELECTIONSISSUER1660190FOR166019FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Susan Desmond-HellmannDIRECTOR ELECTIONSISSUER1660190FOR166019FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Joseph J. EchevarriaDIRECTOR ELECTIONSISSUER1660190FOR166019FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Scott GottliebDIRECTOR ELECTIONSISSUER1660190FOR166019FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Dan R. LittmanDIRECTOR ELECTIONSISSUER1660190FOR166019FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Shantanu NarayenDIRECTOR ELECTIONSISSUER1660190FOR166019FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Suzanne Nora JohnsonDIRECTOR ELECTIONSISSUER1660190FOR166019FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: James QuinceyDIRECTOR ELECTIONSISSUER1660190FOR166019FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: James C. SmithDIRECTOR ELECTIONSISSUER1660190FOR166019FOR19 PFIZER INC.717081103US717081103504/23/2026Election of Directors: Cyrus TaraporevalaDIRECTOR ELECTIONSISSUER1660190FOR166019FOR19 PFIZER INC.717081103US717081103504/23/2026Ratify the selection of KPMG LLP as our independent registered public accounting firm for 2026AUDIT-RELATEDISSUER1660190FOR166019FOR19 PFIZER INC.717081103US717081103504/23/2026Approval of the Pfizer Inc. 2019 Stock Plan, as amended April 2026COMPENSATIONISSUER1660190FOR166019FOR19 PFIZER INC.717081103US717081103504/23/20262026 advisory approval of executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER1660190FOR166019FOR19 PFIZER INC.717081103US717081103504/23/2026Adopt an Independent Chair PolicyCORPORATE GOVERNANCESECURITY HOLDER1660190AGAINST166019FOR19 PROTAGONIST THERAPEUTICS, INC.74366E102US74366E102906/17/2026DIRECTOR: Dinesh V. Patel, Ph.D.DIRECTOR ELECTIONSISSUER688550FOR68855FOR19 PROTAGONIST THERAPEUTICS, INC.74366E102US74366E102906/17/2026DIRECTOR: L.T. Williams, MD, PhDDIRECTOR ELECTIONSISSUER688550ABSTAIN68855AGAINST19 PROTAGONIST THERAPEUTICS, INC.74366E102US74366E102906/17/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER688550FOR68855FOR19 PROTAGONIST THERAPEUTICS, INC.74366E102US74366E102906/17/2026To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER688550FOR68855FOR19 PROTAGONIST THERAPEUTICS, INC.74366E102US74366E102906/17/2026To approve the adoption of the Company's 2026 Equity Incentive Plan.COMPENSATIONISSUER688550FOR68855FOR19 PTC THERAPEUTICS, INC.69366J200US69366J200606/02/2026DIRECTOR: Jessica ChutterDIRECTOR ELECTIONSISSUER343610FOR34361FOR19 PTC THERAPEUTICS, INC.69366J200US69366J200606/02/2026DIRECTOR: M.B. Klein, MD MS, FACSDIRECTOR ELECTIONSISSUER343610FOR34361FOR19 PTC THERAPEUTICS, INC.69366J200US69366J200606/02/2026DIRECTOR: Stephanie S. Okey, M.S.DIRECTOR ELECTIONSISSUER343610FOR34361FOR19 PTC THERAPEUTICS, INC.69366J200US69366J200606/02/2026DIRECTOR: J.B. Zeldis, M.D., PhDDIRECTOR ELECTIONSISSUER343610FOR34361FOR19 PTC THERAPEUTICS, INC.69366J200US69366J200606/02/2026Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER343610FOR34361FOR19 PTC THERAPEUTICS, INC.69366J200US69366J200606/02/2026Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER343610FOR34361FOR19 RADNET, INC.750491102US750491102206/02/2026DIRECTOR: Howard G. Berger, M.D.DIRECTOR ELECTIONSISSUER405066400FOR40506FOR19 RADNET, INC.750491102US750491102206/02/2026DIRECTOR: A. Gregory Sorensen M.DDIRECTOR ELECTIONSISSUER405066400FOR40506FOR19 RADNET, INC.750491102US750491102206/02/2026DIRECTOR: Laura P. JacobsDIRECTOR ELECTIONSISSUER405066400ABSTAIN40506AGAINST19 RADNET, INC.750491102US750491102206/02/2026DIRECTOR: Lawrence L. LevittDIRECTOR ELECTIONSISSUER405066400FOR40506FOR19 RADNET, INC.750491102US750491102206/02/2026DIRECTOR: Gregory E. SpurlockDIRECTOR ELECTIONSISSUER405066400FOR40506FOR19 RADNET, INC.750491102US750491102206/02/2026DIRECTOR: David L. SwartzDIRECTOR ELECTIONSISSUER405066400FOR40506FOR19 RADNET, INC.750491102US750491102206/02/2026The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER405066400FOR40506FOR19 RADNET, INC.750491102US750491102206/02/2026An advisory vote to approve the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER405066400FOR40506FOR19 RADNET, INC.750491102US750491102206/02/2026The approval of an amendment and restatement to the Company's Equity Incentive Plan.COMPENSATIONISSUER405066400FOR40506FOR19 REGENXBIO INC.75901B107US75901B107005/29/2026DIRECTOR: Jean Bennett, M.D., PhDDIRECTOR ELECTIONSISSUER812820FOR81282FOR19 REGENXBIO INC.75901B107US75901B107005/29/2026DIRECTOR: A.N. Karabelas, Ph.D.DIRECTOR ELECTIONSISSUER812820FOR81282FOR19 REGENXBIO INC.75901B107US75901B107005/29/2026DIRECTOR: Daniel TasséDIRECTOR ELECTIONSISSUER812820FOR81282FOR19 REGENXBIO INC.75901B107US75901B107005/29/2026To ratify the appointment of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER812820FOR81282FOR19 REGENXBIO INC.75901B107US75901B107005/29/2026Advisory vote on the compensation paid to the Company's executive employees.SECTION 14A SAY-ON-PAY VOTESISSUER812820FOR81282FOR19 REGENXBIO INC.75901B107US75901B107005/29/2026To approve a stock option exchange for our non-executive employees.COMPENSATIONISSUER812820FOR81282FOR19 REGENXBIO INC.75901B107US75901B107005/29/2026To approve a stock option exchange for our executive employees.COMPENSATIONISSUER812820AGAINST81282AGAINST19 RELAY THERAPEUTICS, INC.75943R102US75943R102306/09/2026To elect two class III directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal; Douglas S. IngramDIRECTOR ELECTIONSISSUER1176680FOR117668FOR19 RELAY THERAPEUTICS, INC.75943R102US75943R102306/09/2026To elect two class III directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal; Claire Mazumdar, Ph.D.DIRECTOR ELECTIONSISSUER1176680FOR117668FOR19 RELAY THERAPEUTICS, INC.75943R102US75943R102306/09/2026To consider and act upon an advisory vote on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER1176680FOR117668FOR19 RELAY THERAPEUTICS, INC.75943R102US75943R102306/09/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER1176680FOR117668FOR19 RELAY THERAPEUTICS, INC.75943R102US75943R102306/09/2026To approve an amendment to our Fourth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our common stock from 300,000,000 to 450,000,000;CAPITAL STRUCTUREISSUER1176680FOR117668FOR19 REVOLUTION MEDICINES, INC.76155X100US76155X100006/18/2026DIRECTOR: Alexis BorisyDIRECTOR ELECTIONSISSUER693770FOR69377FOR19 REVOLUTION MEDICINES, INC.76155X100US76155X100006/18/2026DIRECTOR: Mark A Goldsmith MD PhDDIRECTOR ELECTIONSISSUER693770FOR69377FOR19 REVOLUTION MEDICINES, INC.76155X100US76155X100006/18/2026To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026; andAUDIT-RELATEDISSUER693770FOR69377FOR19 REVOLUTION MEDICINES, INC.76155X100US76155X100006/18/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTESISSUER693770FOR69377FOR19 RHYTHM PHARMACEUTICALS, INC.76243J105US76243J105106/24/2026DIRECTOR: David W.J. McGirrDIRECTOR ELECTIONSISSUER1114520FOR111452FOR19 RHYTHM PHARMACEUTICALS, INC.76243J105US76243J105106/24/2026DIRECTOR: David P. Meeker, M.D.DIRECTOR ELECTIONSISSUER1114520FOR111452FOR19 RHYTHM PHARMACEUTICALS, INC.76243J105US76243J105106/24/2026Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1114520FOR111452FOR19 RHYTHM PHARMACEUTICALS, INC.76243J105US76243J105106/24/2026Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER1114520FOR111452FOR19 ROIVANT SCIENCES LTD.G76279101BMG76279101709/10/2025DIRECTOR: Matthew GlineDIRECTOR ELECTIONSISSUER5242380FOR524238FOR19 ROIVANT SCIENCES LTD.G76279101BMG76279101709/10/2025DIRECTOR: Keith ManchesterDIRECTOR ELECTIONSISSUER5242380FOR524238FOR19 ROIVANT SCIENCES LTD.G76279101BMG76279101709/10/2025DIRECTOR: Melissa EpperlyDIRECTOR ELECTIONSISSUER5242380FOR524238FOR19 ROIVANT SCIENCES LTD.G76279101BMG76279101709/10/2025To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Roivant's independent registered public accounting firm for Roivant's fiscal year ending March 31, 2026, to appoint Ernst & Young LLP as auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for Roivant's fiscal year ending March 31, 2026, and to authorize the Board of Directors, through the Audit Committee, to set the remuneration for Ernst & Young LLP as Roivant's auditor for Roivant's fiscal year ending March 31, 2026.AUDIT-RELATEDCOMPENSATIONISSUER5242380FOR524238FOR19 ROIVANT SCIENCES LTD.G76279101BMG76279101709/10/2025To cast a non-binding, advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER5242380FOR524238FOR19 SAGIMET BIOSCIENCES INC.786700104US786700104906/12/2026DIRECTOR: Jennifer JarrettDIRECTOR ELECTIONSISSUER2202270ABSTAIN220227AGAINST19 SAGIMET BIOSCIENCES INC.786700104US786700104906/12/2026DIRECTOR: Anne Phillips, M.D.DIRECTOR ELECTIONSISSUER2202270FOR220227FOR19 SAGIMET BIOSCIENCES INC.786700104US786700104906/12/2026DIRECTOR: David HappelDIRECTOR ELECTIONSISSUER2202270FOR220227FOR19 SAGIMET BIOSCIENCES INC.786700104US786700104906/12/2026DIRECTOR: George Kemble, Ph.D.DIRECTOR ELECTIONSISSUER2202270FOR220227FOR19 SAGIMET BIOSCIENCES INC.786700104US786700104906/12/2026The ratification of the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER2202270FOR220227FOR19 SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103006/04/2026DIRECTOR: David HallalDIRECTOR ELECTIONSISSUER300770FOR30077FOR19 SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103006/04/2026DIRECTOR: Kristina BurowDIRECTOR ELECTIONSISSUER300770FOR30077FOR19 SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103006/04/2026DIRECTOR: Michael GilmanDIRECTOR ELECTIONSISSUER300770ABSTAIN30077AGAINST19 SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103006/04/2026DIRECTOR: Katie PengDIRECTOR ELECTIONSISSUER300770FOR30077FOR19 SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103006/04/2026To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER300770FOR30077FOR19 SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103006/04/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER300770AGAINST30077AGAINST19 STOKE THERAPEUTICS, INC.86150R107US86150R107706/03/2026DIRECTOR: G. Clare Kahn, Ph.D.DIRECTOR ELECTIONSISSUER1326560FOR132656FOR19 STOKE THERAPEUTICS, INC.86150R107US86150R107706/03/2026DIRECTOR: Adrian Krainer, Ph.D.DIRECTOR ELECTIONSISSUER1326560ABSTAIN132656AGAINST19 STOKE THERAPEUTICS, INC.86150R107US86150R107706/03/2026DIRECTOR: Julie Anne SmithDIRECTOR ELECTIONSISSUER1326560FOR132656FOR19 STOKE THERAPEUTICS, INC.86150R107US86150R107706/03/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1326560FOR132656FOR19 STOKE THERAPEUTICS, INC.86150R107US86150R107706/03/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1326560FOR132656FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026DIRECTOR: Robert W. DugganDIRECTOR ELECTIONSISSUER10259213658FOR102592FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026DIRECTOR: Mahkam ZanganehDIRECTOR ELECTIONSISSUER10259213658FOR102592FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026DIRECTOR: Manmeet S. SoniDIRECTOR ELECTIONSISSUER10259213658FOR102592FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026DIRECTOR: Kenneth A. ClarkDIRECTOR ELECTIONSISSUER10259213658FOR102592FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026DIRECTOR: Robert BoothDIRECTOR ELECTIONSISSUER10259213658FOR102592FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026DIRECTOR: Alessandra CesanoDIRECTOR ELECTIONSISSUER10259213658FOR102592FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026DIRECTOR: Yu (Michelle) XiaDIRECTOR ELECTIONSISSUER10259213658FOR102592FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026DIRECTOR: Mostafa RonaghiDIRECTOR ELECTIONSISSUER10259213658FOR102592FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026DIRECTOR: Jeff HuberDIRECTOR ELECTIONSISSUER10259213658FOR102592FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026Ratification of the appointment of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER10259213658FOR102592FOR19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026Approval, by a non-binding advisory vote, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER10259213658AGAINST102592AGAINST19 SUMMIT THERAPEUTICS INC.86627T108US86627T108806/10/2026Approval of an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to Increase the Number of Shares of Common Stock.COMPENSATIONISSUER10259213658FOR102592FOR19 SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026Election of Directors Pierre LegaultDIRECTOR ELECTIONSISSUER243200FOR24320FOR19 SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026Election of Directors Michael A. MetzgerDIRECTOR ELECTIONSISSUER243200FOR24320FOR19 SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2026 proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER243200FOR24320FOR19 SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026To ratify the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER243200FOR24320FOR19 SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026To approve the Syndax Pharmaceuticals, Inc. 2026 Equity Incentive Plan.COMPENSATIONISSUER243200FOR24320FOR19 SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026To approve the Syndax Pharmaceuticals, Inc. 2026 Employee Stock Purchase Plan.COMPENSATIONISSUER243200FOR24320FOR19 TEMPUS AI, INC.88023B103US88023B103505/21/2026DIRECTOR: Eric LefkofskyDIRECTOR ELECTIONSISSUER4672131102FOR46721FOR19 TEMPUS AI, INC.88023B103US88023B103505/21/2026DIRECTOR: Peter J. BarrisDIRECTOR ELECTIONSISSUER4672131102ABSTAIN46721AGAINST19 TEMPUS AI, INC.88023B103US88023B103505/21/2026DIRECTOR: Eric D. BelcherDIRECTOR ELECTIONSISSUER4672131102FOR46721FOR19 TEMPUS AI, INC.88023B103US88023B103505/21/2026DIRECTOR: Jennifer A. DoudnaDIRECTOR ELECTIONSISSUER4672131102FOR46721FOR19 TEMPUS AI, INC.88023B103US88023B103505/21/2026DIRECTOR: David R. EpsteinDIRECTOR ELECTIONSISSUER4672131102FOR46721FOR19 TEMPUS AI, INC.88023B103US88023B103505/21/2026DIRECTOR: Wayne A.I. Frederick MDDIRECTOR ELECTIONSISSUER4672131102FOR46721FOR19 TEMPUS AI, INC.88023B103US88023B103505/21/2026DIRECTOR: Scott Gottlieb, M.D.DIRECTOR ELECTIONSISSUER4672131102FOR46721FOR19 TEMPUS AI, INC.88023B103US88023B103505/21/2026DIRECTOR: Theodore J. LeonsisDIRECTOR ELECTIONSISSUER4672131102FOR46721FOR19 TEMPUS AI, INC.88023B103US88023B103505/21/2026DIRECTOR: Nadja West, M.D.DIRECTOR ELECTIONSISSUER4672131102FOR46721FOR19 TEMPUS AI, INC.88023B103US88023B103505/21/2026To ratify the appointment by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER4672131102FOR46721FOR19 TEMPUS AI, INC.88023B103US88023B103505/21/2026To consider a non-binding advisory vote on the frequency of future stockholder votes to approve the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER46721311021 YEAR46721AGAINST19 TEVA PHARMACEUTICAL INDUSTRIES LIMITED881624209US881624209805/28/2026TO APPOINT DR. SOL J. BARER TO SERVE AS A DIRECTOR UNTIL TEVA'S 2029 ANNUAL MEETING OF SHAREHOLDERS Dr. Sol J. BarerDIRECTOR ELECTIONSISSUER2122050FOR212205FOR19 TEVA PHARMACEUTICAL INDUSTRIES LIMITED881624209US881624209805/28/2026TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION FOR TEVA'S NAMED EXECUTIVE OFFICERSSECTION 14A SAY-ON-PAY VOTESISSUER2122050FOR212205FOR19 TEVA PHARMACEUTICAL INDUSTRIES LIMITED881624209US881624209805/28/2026TO APPOINT KESSELMAN & KESSELMAN, A MEMBER OF PRICEWATERHOUSECOOPERS INTERNATIONAL LTD., AS TEVA'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM UNTIL TEVA'S 2027 ANNUAL MEETING OF SHAREHOLDERSAUDIT-RELATEDISSUER2122050FOR212205FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors Marc N. CasperDIRECTOR ELECTIONSISSUER90620FOR9062FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors Nelson J. ChaiDIRECTOR ELECTIONSISSUER90620FOR9062FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors Ruby R. ChandyDIRECTOR ELECTIONSISSUER90620FOR9062FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors C. Martin HarrisDIRECTOR ELECTIONSISSUER90620FOR9062FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors Tyler JacksDIRECTOR ELECTIONSISSUER90620FOR9062FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors Jennifer M. JohnsonDIRECTOR ELECTIONSISSUER90620FOR9062FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors R. Alexandra KeithDIRECTOR ELECTIONSISSUER90620FOR9062FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors Karen S. LynchDIRECTOR ELECTIONSISSUER90620FOR9062FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors Debora L. SparDIRECTOR ELECTIONSISSUER90620FOR9062FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors Scott M. SperlingDIRECTOR ELECTIONSISSUER90620FOR9062FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Election of Directors Dion J. WeislerDIRECTOR ELECTIONSISSUER90620FOR9062FOR19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026An advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER90620AGAINST9062AGAINST19 THERMO FISHER SCIENTIFIC INC.883556102US883556102305/20/2026Ratification of the Audit Committee's selection of PricewaterhouseCoopers LLP as the Company's independent auditors for 2026.AUDIT-RELATEDISSUER90620FOR9062FOR19 TSCAN THERAPEUTICS, INC.89854M101US89854M101805/20/2026DIRECTOR: Katina DortonDIRECTOR ELECTIONSISSUER4070100FOR407010FOR19 TSCAN THERAPEUTICS, INC.89854M101US89854M101805/20/2026DIRECTOR: R. Keith WoodsDIRECTOR ELECTIONSISSUER4070100FOR407010FOR19 TSCAN THERAPEUTICS, INC.89854M101US89854M101805/20/2026To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026AUDIT-RELATEDISSUER4070100FOR407010FOR19 TSCAN THERAPEUTICS, INC.89854M101US89854M101805/20/2026To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of voting common stock from 300,000,000 shares to 600,000,000 sharesCAPITAL STRUCTUREISSUER4070100FOR407010FOR19 TSCAN THERAPEUTICS, INC.89854M101US89854M101805/20/2026To approve a proposal to adjourn the Annual Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposal No. 3CORPORATE GOVERNANCEISSUER4070100FOR407010FOR19 UCB SAB93562120BE000373953004/30/2026Approve Financial Statements, Allocation of Income, and Dividends of EUR 1.45 per ShareCORPORATE GOVERNANCEISSUER442870FOR44287FOR19 UCB SAB93562120BE000373953004/30/2026Approve Remuneration ReportSECTION 14A SAY-ON-PAY VOTESISSUER442870FOR44287FOR19 UCB SAB93562120BE000373953004/30/2026Approve Discharge of DirectorsDIRECTOR ELECTIONSISSUER442870FOR44287FOR19 UCB SAB93562120BE000373953004/30/2026Approve Discharge of AuditorsAUDIT-RELATEDISSUER442870FOR44287FOR19 UCB SAB93562120BE000373953004/30/2026Reelect Jean-Christophe Tellier as DirectorDIRECTOR ELECTIONSISSUER442870FOR44287FOR19 UCB SAB93562120BE000373953004/30/2026Reelect Cedric van Rijckevorsel as DirectorDIRECTOR ELECTIONSISSUER442870FOR44287FOR19 UCB SAB93562120BE000373953004/30/2026Approve Renewal of Change-of-Control Clause Re: EMTN Program - Art. 7:151 of the BCCACORPORATE GOVERNANCEISSUER442870FOR44287FOR19 UCB SAB93562120BE000373953004/30/2026Renew Authorization to Increase Share Capital within the Framework of Authorized CapitalCAPITAL STRUCTUREISSUER442870FOR44287FOR19 UCB SAB93562120BE000373953004/30/2026Authorize Share Repurchase Program and Reissuance of Repurchased SharesCAPITAL STRUCTUREISSUER442870FOR44287FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Christopher CauseyDIRECTOR ELECTIONSISSUER30800FOR3080FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Richard GiltnerDIRECTOR ELECTIONSISSUER30800FOR3080FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Ray KurzweilDIRECTOR ELECTIONSISSUER30800FOR3080FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Jan MalcolmDIRECTOR ELECTIONSISSUER30800FOR3080FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Linda MaxwellDIRECTOR ELECTIONSISSUER30800FOR3080FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Nilda MesaDIRECTOR ELECTIONSISSUER30800FOR3080FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Judy OlianDIRECTOR ELECTIONSISSUER30800FOR3080FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Christopher PatuskyDIRECTOR ELECTIONSISSUER30800FOR3080FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Martine RothblattDIRECTOR ELECTIONSISSUER30800FOR3080FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Louis SullivanDIRECTOR ELECTIONSISSUER30800FOR3080FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Tommy ThompsonDIRECTOR ELECTIONSISSUER30800FOR3080FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Election of Directors Kevin TraceyDIRECTOR ELECTIONSISSUER30800FOR3080FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Advisory resolution to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER30800FOR3080FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan.COMPENSATIONISSUER30800FOR3080FOR19 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER30800FOR3080FOR19 UPSTREAM BIO, INC.91678A107US91678A107906/09/2026DIRECTOR: H. E. Fleming Jr., M.D.DIRECTOR ELECTIONSISSUER565300FOR56530FOR19 UPSTREAM BIO, INC.91678A107US91678A107906/09/2026DIRECTOR: L. Ratcliffe,MBChB, PhDDIRECTOR ELECTIONSISSUER565300FOR56530FOR19 UPSTREAM BIO, INC.91678A107US91678A107906/09/2026To ratify the appointment of PricewaterhouseCoopers LLP as Upstream's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER565300FOR56530FOR19 VAXCYTE, INC.92243G108US92243G108506/15/2026DIRECTOR: Olivier Brandicourt MDDIRECTOR ELECTIONSISSUER335890FOR33589FOR19 VAXCYTE, INC.92243G108US92243G108506/15/2026DIRECTOR: Halley Gilbert, J.D.DIRECTOR ELECTIONSISSUER335890FOR33589FOR19 VAXCYTE, INC.92243G108US92243G108506/15/2026DIRECTOR: Grant E. Pickering MBADIRECTOR ELECTIONSISSUER335890FOR33589FOR19 VAXCYTE, INC.92243G108US92243G108506/15/2026Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER335890FOR33589FOR19 VAXCYTE, INC.92243G108US92243G108506/15/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER335890FOR33589FOR19 VENTYX BIOSCIENCES, INC.92332V107US92332V107003/03/2026To adopt the Agreement and Plan of Merger (as it may be amended from time to time), dated as of January 7, 2026, by and among Eli Lilly and Company, RYLS Merger Corporation ("merger sub"), and Ventyx Biosciences, Inc. (the "merger agreement");EXTRAORDINARY TRANSACTIONSISSUER2226200FOR222620FOR19 VENTYX BIOSCIENCES, INC.92332V107US92332V107003/03/2026To approve, on a non-binding, advisory basis, the compensation that will or may become payable by Ventyx Biosciences, Inc. to its named executive officers in connection with the merger of merger sub with and into Ventyx Biosciences, Inc.; andSECTION 14A SAY-ON-PAY VOTESISSUER2226200FOR222620FOR19 VENTYX BIOSCIENCES, INC.92332V107US92332V107003/03/2026To adjourn the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special meeting.CORPORATE GOVERNANCEISSUER2226200FOR222620FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Sangeeta BhatiaDIRECTOR ELECTIONSISSUER209000FOR20900FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Lloyd CarneyDIRECTOR ELECTIONSISSUER209000FOR20900FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Alan GarberDIRECTOR ELECTIONSISSUER209000FOR20900FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Reshma KewalramaniDIRECTOR ELECTIONSISSUER209000FOR20900FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Michel LagardeDIRECTOR ELECTIONSISSUER209000FOR20900FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Jeffrey LeidenDIRECTOR ELECTIONSISSUER209000FOR20900FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Diana McKenzieDIRECTOR ELECTIONSISSUER209000FOR20900FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Bruce SachsDIRECTOR ELECTIONSISSUER209000FOR20900FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Jennifer SchneiderDIRECTOR ELECTIONSISSUER209000FOR20900FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Nancy ThornberryDIRECTOR ELECTIONSISSUER209000FOR20900FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Election of Directors: Suketu UpadhyayDIRECTOR ELECTIONSISSUER209000ABSTAIN20900AGAINST19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER209000FOR20900FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER209000FOR20900FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Approval of 2026 Stock and Option Plan.COMPENSATIONISSUER209000FOR20900FOR19 VERTEX PHARMACEUTICALS INCORPORATED92532F100US92532F100305/13/2026Shareholder Proposal, if properly presented at the meeting, regarding shareholder right to act by written consent.SHAREHOLDER RIGHTS AND DEFENSESSECURITY HOLDER209000AGAINST20900FOR19 VIGIL NEUROSCIENCE, INC.92673K108US92673K108808/04/2025Adoption of the Agreement and Plan of Merger, dated as of May 21, 2025 (the "Merger Agreement"), by and among Sanofi, a French societe anonyme ("Parent"), Vesper Acquisition Sub Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub") and Vigil Neuroscience, Inc. (the "Company"), pursuant to which, on the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will be merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.EXTRAORDINARY TRANSACTIONSISSUER1313440FOR131344FOR19 VIGIL NEUROSCIENCE, INC.92673K108US92673K108808/04/2025Approval to adjourn the special meeting of stockholders of the Company (the "Special Meeting"), from time to time, if necessary or appropriate, to solicit additional votes for the approval of the proposal to adopt the Merger Agreement if there are insufficient votes at the time of the Special Meeting to adopt the Merger Agreement.CORPORATE GOVERNANCEISSUER1313440FOR131344FOR19 VIKING THERAPEUTICS INC92686J106US92686J106005/19/2026DIRECTOR: J. Matthew SingletonDIRECTOR ELECTIONSISSUER563220FOR56322FOR19 VIKING THERAPEUTICS INC92686J106US92686J106005/19/2026DIRECTOR: S. Kathryn Rouan, Ph DDIRECTOR ELECTIONSISSUER563220ABSTAIN56322AGAINST19 VIKING THERAPEUTICS INC92686J106US92686J106005/19/2026TO RATIFY THE SELECTION OF CBIZ CPAS P.C. AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.AUDIT-RELATEDISSUER563220FOR56322FOR19 VIKING THERAPEUTICS INC92686J106US92686J106005/19/2026TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTESISSUER563220FOR56322FOR19 VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified. Tomas KiselakDIRECTOR ELECTIONSISSUER1731200FOR173120FOR19 VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified. Jennifer K. MosesDIRECTOR ELECTIONSISSUER1731200FOR173120FOR19 VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER1731200FOR173120FOR19 VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1731200FOR173120FOR19 VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER17312001 YEAR173120FOR19 VOR BIOPHARMA INC.929033207US929033207406/11/2026To elect each of the two Class II director nominees set forth in the Proxy Statement to our board of directors, each to serve a three-year term expiring at the 2029 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal: Andrew Levin, M.D., Ph.D.DIRECTOR ELECTIONSISSUER437100FOR43710FOR19 VOR BIOPHARMA INC.929033207US929033207406/11/2026To elect each of the two Class II director nominees set forth in the Proxy Statement to our board of directors, each to serve a three-year term expiring at the 2029 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal: Fouad Namouni, M.D.DIRECTOR ELECTIONSISSUER437100FOR43710FOR19 VOR BIOPHARMA INC.929033207US929033207406/11/2026To approve the amendment and restatement of our Amended and Restated 2021 Equity Incentive Plan.COMPENSATIONISSUER437100AGAINST43710AGAINST19 VOR BIOPHARMA INC.929033207US929033207406/11/2026To ratify the selection by the audit committee of the board of directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER437100FOR43710FOR19 VOYAGER THERAPEUTICS, INC.92915B106US92915B106106/09/2026DIRECTOR: James A. GeraghtyDIRECTOR ELECTIONSISSUER1417870FOR141787FOR19 VOYAGER THERAPEUTICS, INC.92915B106US92915B106106/09/2026DIRECTOR: Steven Hyman, M.D.DIRECTOR ELECTIONSISSUER1417870FOR141787FOR19 VOYAGER THERAPEUTICS, INC.92915B106US92915B106106/09/2026DIRECTOR: A. Sandrock M.D., Ph.D.DIRECTOR ELECTIONSISSUER1417870FOR141787FOR19 VOYAGER THERAPEUTICS, INC.92915B106US92915B106106/09/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1417870FOR141787FOR19 VOYAGER THERAPEUTICS, INC.92915B106US92915B106106/09/2026To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1417870FOR141787FOR19 VOYAGER THERAPEUTICS, INC.92915B106US92915B106106/09/2026To approve an amendment to the Fifth Amended and Restated Certificate of Incorporation of Voyager Therapeutics, Inc. to increase the number of authorized shares of the Company's capital stock from 125,000,000 shares to 245,000,000 shares and increase the number of authorized shares of common stock from 120,000,000 shares of common stock to 240,000,000 shares of common stock.CAPITAL STRUCTUREISSUER1417870FOR141787FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Dr. Flemming Ornskov, M.D., M.P.H.DIRECTOR ELECTIONSISSUER140150FOR14015FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Linda BaddourDIRECTOR ELECTIONSISSUER140150FOR14015FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Udit Batra, Ph.D.DIRECTOR ELECTIONSISSUER140150FOR14015FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Dan BrennanDIRECTOR ELECTIONSISSUER140150FOR14015FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Richard FearonDIRECTOR ELECTIONSISSUER140150FOR14015FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Claire M. Fraser, Ph.D.DIRECTOR ELECTIONSISSUER140150FOR14015FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Pearl S. Huang, Ph.D.DIRECTOR ELECTIONSISSUER140150FOR14015FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Wei JiangDIRECTOR ELECTIONSISSUER140150FOR14015FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Heather KnightDIRECTOR ELECTIONSISSUER140150FOR14015FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Christopher A. KueblerDIRECTOR ELECTIONSISSUER140150FOR14015FOR19 WATERS CORPORATION941848103US941848103505/21/2026To elect directors to serve for the ensuing year and until their successors are elected; Mark VergnanoDIRECTOR ELECTIONSISSUER140150FOR14015FOR19 WATERS CORPORATION941848103US941848103505/21/2026To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; andAUDIT-RELATEDISSUER140150FOR14015FOR19 WATERS CORPORATION941848103US941848103505/21/2026To approve, on a non-binding, advisory basis, the compensation of the Company's executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER140150FOR14015FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025The election of the nominees for director: Paul B. Bolno, M.D., MBADIRECTOR ELECTIONSISSUER1511160FOR151116FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025The election of the nominees for director: Mark H. N. Corrigan, M.D.DIRECTOR ELECTIONSISSUER1511160FOR151116FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025The election of the nominees for director: Christian HenryDIRECTOR ELECTIONSISSUER1511160AGAINST151116AGAINST19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025The election of the nominees for director: Peter Kolchinsky, Ph.D.DIRECTOR ELECTIONSISSUER1511160FOR151116FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025The election of the nominees for director: Adrian RawcliffeDIRECTOR ELECTIONSISSUER1511160FOR151116FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025The election of the nominees for director: Ken TakanashiDIRECTOR ELECTIONSISSUER1511160FOR151116FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025The election of the nominees for director: Aik Na TanDIRECTOR ELECTIONSISSUER1511160FOR151116FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025The election of the nominees for director: Gregory L. Verdine, Ph.D.DIRECTOR ELECTIONSISSUER1511160FOR151116FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025The election of the nominees for director: Heidi L. Wagner, J.D.DIRECTOR ELECTIONSISSUER1511160FOR151116FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve the re-appointment of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2025, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP's remuneration for services provided through the date of our 2026 Annual General Meeting of Shareholders.AUDIT-RELATEDCOMPENSATIONISSUER1511160FOR151116FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve our payment of cash and equity-based compensation to non-employee directors for service on the Board of Directors and its committees, in the manner and on the basis set forth under "Proposal 3: Non-Employee Directors' Compensation" in the proxy statement.COMPENSATIONISSUER1511160FOR151116FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve a proposed amendment to our 2021 Equity Incentive Plan, as amended, in the manner and on the basis as set forth under "Proposal 4: Approval of an Amendment to the 2021 Equity Incentive Plan, as amended" in the proxy statement.COMPENSATIONISSUER1511160FOR151116FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To authorize the Board of Directors to allot and issue Ordinary Shares of Wave Life Sciences Ltd.CAPITAL STRUCTUREISSUER1511160AGAINST151116AGAINST19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve, by a non-binding advisory vote, the compensation of our named executive officers as disclosed in the proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER1511160FOR151116FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471608/05/2025To approve, on a non-binding, advisory basis only, the frequency of holding future shareholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER15111601 YEAR151116FOR19 WAVE LIFE SCIENCES LTD.Y95308105SG999901471606/22/2026To approve the scheme of arrangement under Singapore law among Wave Life Sciences Ltd., a public company limited by shares incorporated under the laws of the Republic of Singapore ("Wave-Singapore"), the shareholders of Wave-Singapore and Wave Life Sciences, Inc., a Delaware corporation, subject to approval of the High Court of the Republic of Singapore, as set forth in Wave-Singapore's notice of, and proxy statement relating to, the Special Meeting of Wave-Singapore shareholders.CAPITAL STRUCTUREISSUER962830FOR96283FOR19 WUXI BIOLOGICS (CAYMAN) INC.G97008117KYG97008117306/10/2026Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER11525000FOR1152500FOR19 WUXI BIOLOGICS (CAYMAN) INC.G97008117KYG97008117306/10/2026Elect Ge Li as DirectorDIRECTOR ELECTIONSISSUER11525000AGAINST1152500AGAINST19 WUXI BIOLOGICS (CAYMAN) INC.G97008117KYG97008117306/10/2026Elect Kenneth Walton Hitchner III as DirectorDIRECTOR ELECTIONSISSUER11525000FOR1152500FOR19 WUXI BIOLOGICS (CAYMAN) INC.G97008117KYG97008117306/10/2026Elect Jue Chen as DirectorDIRECTOR ELECTIONSISSUER11525000FOR1152500FOR19 WUXI BIOLOGICS (CAYMAN) INC.G97008117KYG97008117306/10/2026Authorize Board of Directors or Any Duly Authorized Board Committee to Fix the Directors' RemunerationCOMPENSATIONISSUER11525000FOR1152500FOR19 WUXI BIOLOGICS (CAYMAN) INC.G97008117KYG97008117306/10/2026Approve Deloitte Touche Tohmatsu as Auditors and Authorize the Board of Directors or Any Duly Authorized Board Committee to Fix Their RemunerationAUDIT-RELATEDISSUER11525000AGAINST1152500AGAINST19 WUXI BIOLOGICS (CAYMAN) INC.G97008117KYG97008117306/10/2026Approve Issuance of Equity or Equity-Linked Securities without Preemptive RightsCAPITAL STRUCTUREISSUER11525000FOR1152500FOR19 WUXI BIOLOGICS (CAYMAN) INC.G97008117KYG97008117306/10/2026Authorize Repurchase of Issued Share CapitalCAPITAL STRUCTUREISSUER11525000FOR1152500FOR19 ZEALAND PHARMA A/SK9898X127DK006025781405/26/2026Elect Camilla Sylvest as New DirectorDIRECTOR ELECTIONSISSUER469200FOR46920FOR19 ZEALAND PHARMA A/SK9898X127DK006025781405/26/2026Authorize Editorial Changes to Adopted Resolutions in Connection with Registration with Danish AuthoritiesCORPORATE GOVERNANCEISSUER469200FOR46920FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026ACCEPT FINANCIAL STATEMENTS AND STATUTORY REPORTSCORPORATE GOVERNANCEISSUER469200FOR46920FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026APPROVE ALLOCATION OF INCOME AND OMISSION OF DIVIDENDSCAPITAL STRUCTUREISSUER469200FOR46920FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026REELECT ALF GUNNAR MARTIN NICKLASSON AS DIRECTORDIRECTOR ELECTIONSISSUER469200FOR46920FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026REELECT KIRSTEN AARUP DREJER AS DIRECTORDIRECTOR ELECTIONSISSUER469200FOR46920FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026REELECT LEONARD KRUIMER AS DIRECTORDIRECTOR ELECTIONSISSUER469200FOR46920FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026REELECT ELAINE SULLIVAN AS DIRECTORDIRECTOR ELECTIONSISSUER469200FOR46920FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026REELECT ENRIQUE CONTERNO AS DIRECTORDIRECTOR ELECTIONSISSUER469200FOR46920FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026ELECT IRIS LOEW FRIEDRICH AS NEW DIRECTORDIRECTOR ELECTIONSISSUER469200FOR46920FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026RATIFY PRICEWATERHOUSECOOPERS AS AUDITORSAUDIT-RELATEDISSUER469200FOR46920FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026AUTHORIZE SHARE REPURCHASE PROGRAMCAPITAL STRUCTUREISSUER469200FOR46920FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026APPROVE REMUNERATION REPORT (ADVISORY VOTE)SECTION 14A SAY-ON-PAY VOTESISSUER469200FOR46920FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026APPROVE REMUNERATION OF DIRECTORS IN THE AMOUNT OF DKK 100,000 FOR EACH DIRECTOR, AND 5,000 RSU FOR CHAIR, 1,000 RSU FOR VICE CHAIR AND 1,500 RSU FOR OTHER DIRECTORS; APPROVE REMUNERATION FOR COMMITTEE WORK IN RSUSCOMPENSATIONISSUER469200FOR46920FOR19 ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026AUTHORIZE EDITORIAL CHANGES TO ADOPTED RESOLUTIONS IN CONNECTION WITH REGISTRATION WITH DANISH AUTHORITIESCORPORATE GOVERNANCEISSUER469200FOR46920FOR19